US20180066283A1 - Widespread gene delivery to motor neurons using peripheral injection of aav vectors - Google Patents
Widespread gene delivery to motor neurons using peripheral injection of aav vectors Download PDFInfo
- Publication number
- US20180066283A1 US20180066283A1 US15/713,347 US201715713347A US2018066283A1 US 20180066283 A1 US20180066283 A1 US 20180066283A1 US 201715713347 A US201715713347 A US 201715713347A US 2018066283 A1 US2018066283 A1 US 2018066283A1
- Authority
- US
- United States
- Prior art keywords
- cells
- aav
- vectors
- injection
- gfp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002161 motor neuron Anatomy 0.000 title claims abstract description 54
- 239000013598 vector Substances 0.000 title claims description 61
- 238000002347 injection Methods 0.000 title abstract description 47
- 239000007924 injection Substances 0.000 title abstract description 47
- 230000002093 peripheral effect Effects 0.000 title abstract description 22
- 238000001476 gene delivery Methods 0.000 title description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 102000004169 proteins and genes Human genes 0.000 claims description 32
- 230000003612 virological effect Effects 0.000 claims description 20
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims description 18
- 210000000234 capsid Anatomy 0.000 claims description 18
- 150000007523 nucleic acids Chemical group 0.000 claims description 17
- 239000013609 scAAV vector Substances 0.000 claims description 12
- 230000010076 replication Effects 0.000 claims description 7
- 230000002950 deficient Effects 0.000 claims description 5
- 241000702421 Dependoparvovirus Species 0.000 claims description 4
- 230000004083 survival effect Effects 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 abstract description 64
- 239000013607 AAV vector Substances 0.000 abstract description 60
- 210000000278 spinal cord Anatomy 0.000 abstract description 59
- 210000003169 central nervous system Anatomy 0.000 abstract description 51
- 238000000034 method Methods 0.000 abstract description 31
- 210000004556 brain Anatomy 0.000 abstract description 26
- 230000001225 therapeutic effect Effects 0.000 abstract description 24
- 230000008499 blood brain barrier function Effects 0.000 abstract description 21
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 14
- 210000004498 neuroglial cell Anatomy 0.000 abstract description 14
- 241000124008 Mammalia Species 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 6
- 210000002569 neuron Anatomy 0.000 abstract description 6
- 230000009885 systemic effect Effects 0.000 abstract description 5
- 208000005264 motor neuron disease Diseases 0.000 abstract description 4
- 239000005090 green fluorescent protein Substances 0.000 description 57
- 241000699670 Mus sp. Species 0.000 description 36
- 108700019146 Transgenes Proteins 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000010361 transduction Methods 0.000 description 17
- 230000026683 transduction Effects 0.000 description 17
- 238000007912 intraperitoneal administration Methods 0.000 description 14
- 210000003205 muscle Anatomy 0.000 description 14
- 210000003161 choroid Anatomy 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 12
- 238000010253 intravenous injection Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 10
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 9
- 208000002320 spinal muscular atrophy Diseases 0.000 description 9
- 210000003059 ependyma Anatomy 0.000 description 8
- 238000010255 intramuscular injection Methods 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000013644 scAAV2 vector Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012744 immunostaining Methods 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 5
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 5
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 210000001353 entorhinal cortex Anatomy 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 4
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 210000005056 cell body Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 4
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- -1 carrier Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000002518 glial effect Effects 0.000 description 3
- 210000001753 habenula Anatomy 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000003442 median eminence Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 210000002804 pyramidal tract Anatomy 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000013216 cat model Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000004289 cerebral ventricle Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012502 diagnostic product Substances 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 210000000337 motor cortex Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QVZVEEALAXDABJ-UHFFFAOYSA-N 4-(trifluoromethyl)-2-[5-(trifluoromethyl)-2,3-dihydrobenzimidazol-1-yl]phenol Chemical compound OC1=CC=C(C(F)(F)F)C=C1N1C2=CC=C(C(F)(F)F)C=C2NC1 QVZVEEALAXDABJ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023345 Autoimmune Diseases of the Nervous System Diseases 0.000 description 1
- 108091005658 Basic proteases Proteins 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101150077194 CAP1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 1
- 101001005139 Homo sapiens Protein limb expression 1 homolog Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 101150058308 LIX1 gene Proteins 0.000 description 1
- 208000033868 Lysosomal disease Diseases 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 1
- 206010056893 Mucopolysaccharidosis VII Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100438378 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fac-1 gene Proteins 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100026042 Protein limb expression 1 homolog Human genes 0.000 description 1
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000032930 Spastic paraplegia Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Substances [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000003164 cauda equina Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
- 229960002140 medetomidine Drugs 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000025919 mucopolysaccharidosis type 7 Diseases 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 230000007441 retrograde transport Effects 0.000 description 1
- 238000004621 scanning probe microscopy Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000031998 transcytosis Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000032527 type III spinal muscular atrophy Diseases 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Definitions
- the present invention relates to compositions and methods for delivering genes to cells of the central nervous system in mammals.
- the invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes.
- the invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons, as well as other cells in the central nervous system.
- the invention may be used in any mammal, including human subjects.
- MN diseases such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) or Kennedy's disease, are neurodegenerative disorders characterised by the selective degeneration of MNs in the spinal cord, brainstem and/or motor cortex (Monani 2005; Pasinelli and Brown 2006); (MacLean, Warne et al. 1996).
- BBB blood-brain-barrier
- This anatomical and physiological barrier is formed by tight junctions between the endothelial cells of the central nervous system (CNS) capillaries and prevents easy passage of molecules between the circulation and the CNS (Scherrmann 2002).
- CNS central nervous system
- Injection of the viral vectors into the cerebral ventricles was also used in the aim to transduce the epithelial cells of the choroids plexus and ependyma, mediating secretion of the therapeutic proteins in the cerebrospinal fluid (CSF) and further diffusion through the CNS parenchyma (Passini and Wolfe 2001).
- CSF cerebrospinal fluid
- Passini and Wolfe 2001 diffusion of the recombinant proteins to the whole nervous tissue was far from being optimal, and again, the potential risks related to the surgical procedure is an obstacle to the clinical application of this method.
- An alternative non-invasive strategy was further developed using retrograde axonal transport of viral vectors to MN through intramuscular (i.m.) injections.
- Gene vectors such as adenovirus, adeno-associated vector (AAV) or equine-anemia viruses pseudotyped with the rabies G glycoprotein (EIAV) indeed undergo retrograde transport along the MN axons after i.m. injections, and were successfully used to transduce lower MN in experimental animals (Finiels et al., 1995; Kaspar et al., 2003; Azzouz et al., 2004).
- the clinical value of this method remains questionable due, in particular, to the large number of both injection sites and viral particles that would be needed for targeting MN in pathologies that affect most of the patient's motor units.
- the present invention relates to novel compositions and methods for the delivery of therapeutic products to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering genes into the motor neurons or glial cells of mammalian subjects through peripheral administration of AAV vectors.
- An object of this invention more specifically relates to the use of an AAV vector comprising a gene of interest (e.g., encoding a therapeutic or diagnostic product) for the manufacture of a medicament for delivering the gene to cells in the central nervous system, particularly motor neurons or glial cells, by peripheral administration of said AAV vector to said subject.
- a gene of interest e.g., encoding a therapeutic or diagnostic product
- An other object of this invention relates to the use of an AAV vector comprising a gene of interest (e.g., encoding a therapeutic or diagnostic product) for the manufacture of a medicament for delivering the gene to spinal cord motor neurons by peripheral administration of said AAV vector to said subject.
- a gene of interest e.g., encoding a therapeutic or diagnostic product
- a further object of this invention resides in a method of delivering a gene to cells in the central nervous system, particularly motor neurons or glial cells, in a mammal, the method comprising administering to the mammal by peripheral route an AAV vector comprising said gene, said administration allowing infection of cells in the central nervous system, particularly motor neurons or glial cells, by said AAV vectors and thereby delivery of said gene to cells in the central nervous system, particularly motor neurons or glial cells.
- An object of this invention also relates to the use of an AAV vector comprising a therapeutic gene for the manufacture of a medicament for treating a motor neuron disorder in a subject, wherein said AAV vector is administered by peripheral injection to said subject, said administration causing infection of (spinal cord) motor neurons and expression of the gene in (spinal cord) motor neurons.
- Another object of this invention relates to the use of an AAV vector for the manufacture of a medicament for producing a therapeutic protein or RNA into (spinal cord) motor neurons of a subject by peripheral injection of said vector.
- the invention also relates to the use of an AAV vector for delivering a gene to cells in the central nervous system, particularly motor neurons or glial cells, by crossing the blood brain barrier.
- the invention also relates to a method of gene therapy across the blood brain barrier in a mammalian subject, the method comprising the peripheral administration of an AAV vector to the subject.
- a further object of this invention is a method of genetically modifying cells in the central nervous system, particularly motor neurons in a mammalian subject, the method comprising peripherally administering AAV vectors to the subject.
- the invention also relates to the use of an AAV vector for the manufacture of a medicament for delivering a gene to the spinal cord by peripheral administration of the AAV vector.
- the invention also resides in a method of gene delivery to the spinal cord of a subject, the method comprising peripherally administering to the subject an AAV vector comprising said gene.
- FIG. 1 a - c Widespread gene delivery to the neonatal mouse muscles and CNS after intramuscular AAV injection (blue: mSEAP histochemical staining). Representative cross sections of the (a) gastrocnemius muscle (b) brain (3rd ventricle) and (c) spinal cord at 3 days (PN4) or 7 days (PN8) after injection of ss- or scAAV1 or AAV9.
- FIG. 2 a - d Widespread gene delivery to the neonatal mouse muscles and CNS after intraperitoneal AAV injection (blue: mSEAP histochemical staining).
- Representative tissue sections of the (a) diaphragm muscle (b) cerebral 3 rd ventricle (arrows: mSEAP expressing choroids plexus cells; arrowheads: ependymal cells) (c) CNS parenchyma (arrows: neuronal cells).
- FIG. 3 a - h Intraperitoneal delivery of self-complementary AA9-GFP mediates CNS transduction in neonatal mice. Representative brain and spinal cord cross sections treated for GFP immunohistochemistry 7 days after AAV delivery. Transgene expression was detected in (a) the choroids plexus epithelial cells (b) hippocampal cells with a neuronal (arrowhead and top box) and glial (arrow and bottom box) morphology (c) cells of the entorhinal cortex (arrows indicate cells with a typical neuronal morphology) (d, e) cells of the spinal cord (the arrow indicates a GFP-labelled cell with a motor neuron morphology) and (f) sensory fibers in the cervical spinal cord. Scale bar 40 ⁇ m.
- FIG. 4 a - f Intramuscular delivery of self-complementary AAV9 vectors allows transduction of CNS cells in neonatal mice. Brain and spinal cord histological sections were treated with GFP immunohistochemistry 7 days after AAV injection. Transgene expression was detected in (a) the epithelial cells of the choroids plexus (arrow) and the ependyma (arrowheads) (b,c) neural cells of the septum and (d, e) of the entorhinal cortex and (f) the corticospinal tract at the level of the pyramidal decussation in the cervical spinal cord (arrows). Scale bar 20 ⁇ m.
- FIG. 5 a - m Intravenous delivery of self-complementary AAV9 vectors mediate GFP expression in the CNS of neonatal mice. Representative photomicrographs of brain and spinal cord histological sections treated for GFP immunostaining 7 days after AAV injection. GFP-positive cells were detected in (a) the epithelial cells of the choroids plexus (arrow) and the ependyma (arrowheads) (c) brain blood vessels (d,f) hippocampal cells with a neuronal (arrow) and glial (arrowhead) morphology (g) neuron-like cells of the entorhinal cortex.
- FIG. 6 a - e GFP-expressing single-stranded AAV9 vectors mediate transgene expression in the CNS of neonatal mice.
- GFP-positive cells in (a) the choroids plexus (asterisk), the hippocampus (arrowhead and box) and the habenular nucleus (arrow) (b) the median eminence and (c-e) motor neuron-like cells in the ventral spinal cord.
- FIG. 7 a - h Recombinant AAV9 vectors mediate transgene expression in the adult mouse CNS.
- FIG. 8 a - g Intravenously injected recombinant AAV9 vectors mediate transgene expression in the spinal cord of adult mice.
- FIG. 9 a - d Intravenous injection of AAV9-GFP in LIX-1 cats mediates transgene expression throughout the spinal cord. Representative transversal spinal cord sections from a 2 days-old LIX1 heterozygous cat were observed using laser scanning confocal microscopy ( FIG. 9 a,c ) or treated for GFP immunohistochemistry ( FIG. 9 b,d ) 10 days after injection of GFP-expressing scAAV9 into the jugular vein.
- FIG. 10 a - f Intravenous injection of GFP expressing AAV9 (1.5 ⁇ 10+12 vector genome-containing particles of scAAV9-CMV-eGFP) in LIX-1 cats mediates transgene expression in motor neurons.
- FIG. 11 a - l Widespread spinal cord transduction is mediated by i.v. delivery of highly concentrated scAAV9 in adult mice.
- MN motor neuron
- SMA spinal muscular atrophy
- ALS amyotrophic lateral sclerosis
- ss single strand
- sc self-complementary AAV vectors of serotype 1 and 9 intraperitonealy, intramuscularly or intravenously (i.v.) in neonatal or adult mice and analyzed transgene expression in the central nervous system (CNS).
- Both recombinant ss- and scAAV9 vectors were found to target neural and epithelial brain cells and, importantly, motor neurons and glial cells in the spinal cord.
- the dorsal sensory fibers and the dorsal root ganglions also appeared highly transduced.
- the most impressive transduction efficacy was obtained with i.v. injected scAAV9 vectors.
- AAV vector designates any vector which comprises or derives from components of AAV and is suitable to infect mammalian cells, preferably human cells.
- AAV vector typically designates an AAV type viral particle (or virion) comprising at least a nucleic acid molecule encoding a therapeutic protein.
- the AAV may be derived from various serotypes, including combinations of serotypes (i.e., “pseudotyped” AAV) or from various genomes (e.g. single-stranded or self-complementary).
- the AAV vector may be replication defective and/or targeted.
- Adeno-associated virus is a dependent parvovirus, of approximately twenty nanometers in size. Like other parvoviruses, AAV is a single-stranded, non-enveloped DNA virus, having a genome of about 5000 nucleotides in length, containing two open reading frames. The left-hand open reading frame codes for the proteins responsible for replication (Rep), while the right-hand open reading frame encodes the structural proteins of the capsid (Cap). The open reading frames are flanked by two ITR sequences, which serve as the origin of replication of the viral genome. Furthermore, the genome also contains a packaging sequence, allowing packaging of the viral genome into an AAV capsid.
- AAV requires co-helper functions (which may be provided e.g. by an adenovirus, or by suitable packaging cells or helper plasmids) to undergo a productive infection in cultured cells.
- helper functions which may be provided e.g. by an adenovirus, or by suitable packaging cells or helper plasmids
- the AAV virions essentially enter the cells, migrate to the nucleus as a single-stranded DNA molecule, and integrate into the cells' genome.
- AAV has a broad host range for infectivity, including human cells, is ubiquitous in humans, and is completely non-pathogenic.
- AAV vectors have been designed, produced and used to mediate gene delivery in human subjects, including for therapeutic purposes. Clinical trials are presently ongoing in various countries using AAV vectors.
- AAV vectors for use in gene transfer comprise a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. Such replication defective AAV vectors more preferably lack most or all of the Rep and Cap coding sequences, and essentially retain one or two AAV ITR sequences and a packaging sequence.
- AAV vectors Methods of producing such AAV vectors have been disclosed in the literature, including using packaging cells, auxiliary viruses or plasmids, and/or baculovirus systems (Samulski et al., (1989) J. Virology 63, 3822; Xiao et al., (1998) J. Virology 72, 2224; Inoue et al., (1998) J. Virol. 72, 7024; WO98/22607; WO2005/072364).
- AAV vectors may be prepared or derived from various serotypes of AAVs, which may be even mixed together or with other types of viruses to produce chimeric (e.g. pseudotyped) AAV viruses.
- the AAV vector for use in the present invention is derived from a human AAV virus.
- Such a human AAV may be derived from any known serotype, e.g. from any one of serotypes 1-11, preferably from AAV2, AAV4, AAV6, AAV8 and AAV9, more preferably from AAV6, AAV8 and AAV9, even more preferably from AAV9.
- AAV vectors comprising an AAV2-derived genome (a nucleic acid molecule comprising an AAV2-derived ITR and an AAV2-derived packaging sequence, operatively linked to a nucleic acid encoding a therapeutic protein, preferably two AAV2-derived ITR flanking an AAV2-derived packaging sequence and a nucleic acid encoding a therapeutic protein) in an AAV2-derived capsid; vectors comprising an AAV4-derived genome in an AAV4-derived capsid; vectors comprising an AAV6-derived genome in an AAV6-derived capsid; vectors comprising an AAV8-derived genome in an AAV8-derived capsid; vectors comprising an AAV9-derived genome in an AAV9-derived capsid
- the AAV vector is a pseudotyped AAV vector, i.e. comprises sequences or components originating from at least two distinct AAV serotypes.
- the pseudotyped AAV vector comprises an AAV genome derived from one AAV serotype (for example AAV2), and a capsid derived at least in part from a distinct AAV serotype.
- pseudotyped AAV vectors include, without limitation, vectors comprising an AAV2-derived genome in an AAV4-derived capsid; or vectors comprising an AAV2-derived genome in an AAV6-derived capsid; or vectors comprising an AAV2-derived genome in an AAV8-derived capsid; or vectors comprising an AAV2-derived genome in an AAV9-derived capsid;
- the AAV vector may comprise a modified capsid, including proteins or peptides of non viral origin or structurally modified, to alter the tropism of the vector.
- the capsid may include a ligand of a particular receptor, or a receptor of a particular ligand, to target the vector towards cell type(s) expressing said receptor or ligand, respectively.
- the AAV genome may be either a single stranded nucleic acid or a double stranded, self complementary nucleic acid (McCarty et al., Gene Therapy, 2001), more preferably a self complementary nucleic acid.
- the AAV-derived genome comprises a nucleic acid encoding a therapeutic protein.
- the nucleic acid also comprises regulatory sequences allowing expression and, preferably, secretion of the encoded protein, such as e.g., a promoter, enhancer, polyadenylation signal, internal ribosome entry sites (IRES), sequences encoding protein transduction domains (PTD), and the like.
- the nucleic acid most preferably comprises a promoter region, operably linked to the coding sequence, to cause or improve expression of the therapeutic protein in infected cells.
- Such a promoter may be ubiquitous, tissue-specific, strong, weak, regulated, chimeric, etc., to allow efficient and suitable production of the protein in the infected tissue.
- the promoter may be homologous to the encoded protein, or heterologous, including cellular, viral, fungal, plant or synthetic promoters.
- Most preferred promoters for use in the present invention shall be functional in nervous cells, particularly in human cells, more preferably in motor neurons.
- Examples of such regulated promoters include, without limitation, Tet on/off element-containing promoters, rapamycin-inducible promoters and metallothionein promoters.
- promoters specific for the motor neurons include the promoter of the Calcitonin Gene-Related Peptide (CGRP), a known motor neuron-derived factor.
- Other promoters functional in motor neurons include the promoters of Choline Acetyl Transferase (ChAT), Neuron Specific Enolase (NSE), Synapsin, or ubiquitous promoters including Neuron Specific Silencer Elements (NRSE).
- ubiquitous promoters include viral promoters, particularly the CMV promoter, the RSV promoter, the SV40 promoter, etc. and cellular promoters such as the PGK (phosphoglycerate kinase) promoter.
- the nucleic acid comprises a leader sequence allowing secretion of the encoded protein.
- Fusion of the transgene of interest with a sequence encoding a secretion signal peptide will allow the production of the therapeutic protein in a form that can be secreted from the transduced cell into the CSF.
- signal peptides include the albumin, the 3-glucuronidase, the alkaline protease or the fibronectin secretory signal peptides.
- the transgene is fused with PTD sequences, such as the Tat or VP22 sequences, in order to cause or improve secretion of the therapeutic protein from the transduced cells and re-uptake by neighbour ones.
- PTD sequences such as the Tat or VP22 sequences
- the nucleic acid comprises, operably linker, a promoter and a leader sequence, to allow expression and secretion of the encoded protein.
- the nucleic acid comprises, operably linker, a promoter, a leader sequence and a PTD sequence, to allow expression and secretion of the encoded protein.
- the promoter is specific or functional in motor neurons, i.e., allows (preferential) expression of the transgene in said cells.
- the AAV vectors may be produced by techniques known per se in the art, as further illustrated in the examples.
- peripheral administration includes, without limitation, any administration route which does not imply direct injection into the brain. More particularly, peripheral administration comprises systemic injections, such as intramuscular (i.m.), intravenous (i.v.), intraperitoneal (i.p.), intra-arterial, sub-cutaneous or transdermic injections. Peripheral administration also includes oral administration of AAV vectors (WO96/40954), delivery using implants (WO01/91803), or administration by instillation through the respiratory system, e.g., using sprays, aerosols or any other appropriate formulations.
- systemic injections such as intramuscular (i.m.), intravenous (i.v.), intraperitoneal (i.p.), intra-arterial, sub-cutaneous or transdermic injections.
- Peripheral administration also includes oral administration of AAV vectors (WO96/40954), delivery using implants (WO01/91803), or administration by instillation through the respiratory system, e.g., using sprays, aerosols or any other
- peripheral administration includes peripheral injection, in particular systemic injection, most preferably i.m., i.p. or i.v. injection.
- the doses of AAV vectors may be easily adapted by the skilled artisan, e.g., depending on the disease condition, the subject, the treatment schedule, etc.
- from 10 9 to 10 14 viral genomes (transducing units) are administered per dose in mice, preferably from about 10 11 to 10 13 .
- the doses of AAV vectors to be administered in humans may range from 10 11 to 10 17 viral genomes, preferably from 10 13 to 10 16 .
- a preferred effective dose within the context of this invention is a dose allowing an optimal transduction of the spinal cord cells (motor neurons and/or glial cells).
- the AAV vector may be administered in any suitable form, either as a liquid solution or suspension, as a solid form suitable for solution or suspension in liquid prior to injection, as a gel or as an emulsion.
- the AAV vectors are typically formulated with any appropriate and pharmaceutically acceptable excipient, carrier, adjuvant, diluent, etc.
- the excipient may be a liquid, isotonic solution, buffer, such as a sterile and pyrogen-free water or a sterile and pyrogen-free phosphate-buffered saline solution.
- the excipient may be in particulate form.
- the AAV vectors are typically administered in a “therapeutically-effective” amount, i.e., an amount that is sufficient to alleviate (e.g., decrease, reduce) at least one of the symptoms associated with the disease state, or to provide improvement in the condition of the subject. It should be pointed out that repeated administrations may be performed, if required, using either the same or different peripheral administration route and/or the same or distinct AAV serotypes.
- AAV vectors in particular scAAV vectors
- scAAV vectors administered peripherally cross the blood brain barrier and cause substantial infection of CNS cells. This effect is obtained without the need of using blood-brain barrier disrupting agents.
- Hyperthermia, mannitol, bradykinin and NS1619 are illustrative blood-brain barrier disrupting agents.
- the invention relates to an use or method as defined above, comprising peripheral administration of an AAV vector, preferably a scAAV vector, more preferably a scAAV9 vector, wherein no blood-brain barrier disrupting agent is implemented. Furthermore, the invention relates to an use or method as defined above, wherein no mannitol is injected to the subject.
- the invention relates to an use or method as defined above, further comprising disruption of the blood-brain barrier with a blood-brain barrier disrupting agent or process, to further increase the crossing of the scAAV vectors implemented in the present invention through the blood-brain barrier.
- the invention shows, for the first time, that AAV vectors administered peripherally cross the blood brain barrier and cause substantial infection of CNS cells, particularly of motor neurons throughout the spinal cord.
- the results presented show that infection is effective from the cervical segment to the lumbar segment of the spinal cord, thereby providing a widespread gene delivery into motor neurons.
- the invention may be used to treat a variety of disorders through delivery of a therapeutic product into CNS cells including the motor neurons.
- the therapeutic product may be any protein, peptide or RNA that may alleviate or reduce symptoms that result from an absence or defect in a protein in a cell or subject or that otherwise confers a benefit to a subject.
- therapeutic proteins include growth factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, and any protein known to be mutated in pathological disorders such as the “survival of motor neuron” protein (SMN).
- therapeutic RNA include antisense RNA or RNAi targeting messenger RNAs coding for proteins having a therapeutic interest in any of the diseases mentioned herein below.
- an RNAi targeting the superoxide dismutase enzyme may be coded by an AAV vector as defined above, in view of the treatment of ALS.
- the invention can be used to treat various diseases, including any disease which may be treated or prevented by expressing therapeutic proteins into nervous tissue.
- diseases include CNS disorders, preferably selected from neurodegenerative diseases, neuromuscular diseases, lysosomal diseases, trauma, bone marrow injuries, pain (including neuropathic pain), cancers of the nervous system, demyelinating diseases, autoimmune diseases of the nervous system, neurotoxic syndromes, sleeping disorders.
- diseases include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, Sly disease, Hunter's disease, dementia, paranoia, obsessive compulsive disorder, learning disabilities, amyotrophic lateral sclerosis, spinal muscular atrophy, Charcot-Marie Tooth disease, spinocerebellar ataxia, spastic paraplegia, Kennedy's disease, glioblastoma, neuroblastoma, autism, Gaucher's disease, Hurler's disease, Krabbe's disease and altered behaviors (e. g., disorders in sleeping, perception or cognition).
- the invention may be used in any mammalian, particularly in human subjects, including adults, for preventive or curative treatment.
- the invention can also be used in diagnostic methods, to detect the status or activity or growth of motor neurons in mammalian subjects.
- the vector typically comprises a detectable gene (fluorescent, luminescent, etc.) and is used as a marker.
- the invention can also be used in animal subjects, e.g., to assist in the research of candidate drugs for treating CNS disorders and/or to understand the mechanisms of motor neuron growth, differentiation, activity, etc.
- mice Pregnant and adult (six to eight week old, female) C57Bl/6 mice were purchased from Charles River Laboratories (Les Oncins, France). Neonates were injected on the day of birth (post-natal 1, PN1). SMA cat breeders (heterozygous and affected animals) were obtained from Dr. Fyfe (Laboratory of Comparative Medical Genetics, Michigan, US) and housed in the Center of Boisbonne at the France Veterinary School. Genotyping of SMA kittens was performed as described previously (Fyfe, Menotti-Raymond et al. 2006). Experiments were approved by the regional ethic committee (CREEA).
- AAV2/1 and AAV2/9 vectors were generated by packaging AAV2_based recombinant single-stranded (ss) and self-complementary (sc) genomes in AAV1 and 9 capsids.
- the vectors were produced using a helper-virus free three-plasmid transfection in HEK293 cells with (1) the adenovirus helper plasmid (2) the AAV packaging plasmid encoding the rep2 and cap1 or 9 genes (pLTRCO2 for AAV1 and p5E18-VD2/9 for AAV9) (3) the AAV2 vector plasmid containing mSeAP or GFP (under control of the cytomegalovirus immediate early (CMV IE) promoter) as ss or sc genome (Xiao, Li et al. 1998). This latter plasmid was constructed by deleting the D sequence and the terminal resolution site (trs) site from one of the inverted terminal repeat.
- CMV IE cytomegalovirus immediate early
- the recombinant vectors were purified by double-CsCl ultracentrifugation followed by dialysis against phosphate-buffered saline. Physical particles were quantified by real time PCR for vectors injected in mice and by dot blot hybridisation for vectors injected in kittens and the vectors titers were expressed as viral genome per milliliter (vg/ml).
- mice were injected on the day of birth (post natal 1, PN1).
- Muscles, brains and spinal cords were removed at 1 (PN2), 3 (PN4) or 7 (PN8) days post-injection from neonate mice or 7 and 35 days post-injection from adult mice.
- Adult C57Bl6 mice were anesthetized (xylazine 10 mg/kg, ketamine 100 mg/kg) and perfused intracardially with 0.1 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS.
- Tissues were removed and post-fixed for 4 h in the same solution before being transferred overnight at 4° C. into 15% sucrose for brains and muscles and 30% sucrose for the spinal cords.
- Neonates were decapitated and tissues were immersed in 4% PFA for 4 h before being cryoprotected overnight at 4° C. Samples were frozen in cold isopentane ( ⁇ 50° C.) and serial sections were cut in a cryostat and stored at ⁇ 80° C. for further analysis.
- muscles, brains and spinal cords from neonate mice were removed at 1, 3 and 7 days p.i., frozen in cold isopentane ( ⁇ 50° C.), and maintained at ⁇ 80° C. for extemporal use.
- Brain and spinal cord from adult animals were harvested at 35 days p.i and treated under the same conditions.
- Tissue sections of 16 ⁇ m thick for brain and spinal cord, and 8 ⁇ m thick for muscles were performed in a cryostat and subsequently processed for transgene expression. The sections were fixed with 0.5% glutaraldehyde, washed with PBS and endogenous alkaline phosphatase was heat-inactivated for 30 min at 65° C. Sections were then incubated overnight at 37° C.
- mice For GFP immunohistochemistry in mice, sections were washed in PBS and incubated for 30 min in a solution of hydrogen peroxide (Peroxydase-Blocking solution, Dako) for inhibition of the endogenous peroxidases. After washing in PBS, sections were blocked for one hour at room temperature in PBS with 10 goat serum (Dako) and 0.4% Triton and then incubated overnight with a rabbit polyclonal anti-GFP (Abcam; 1:3000). A biotin-conjugated secondary antibody (Vectastain, 1:200) and the Vectastain Elite ABC kit were used, and DAB staining was revealed with the DAB substrate kit for peroxydase (Vector Laboratories). Sections were dehydrated in alcohol and xylen, and mounted with Eukit.
- Peroxydase-Blocking solution Dako
- GFP immunocytochemistry in cat was realised on 10 ⁇ m spinal cord frozen sections. Briefly, spinal cord sections were permeabilized with 0.2% Tween 20 in PBS (pH 7.4), blocked with 5% goat serum, incubated two nights at 4° C. with polyclonal antibody AB3080 to GFP (Chemicon, 1:50) and incubated with a biotinylated goat anti-rabbit antibody. The immunolabeling was revealed after an incubation with the streptavidine-peroxydase complex by using the diaminobenzidine substrate peroxydase. The sections were counterstained with haematoxylin.
- ChAT choline acetyltransferase
- BCAT choline acetyltransferase goat polyclonal ChAT antibody
- spinal cord sections were blocked with 1% rabbit serum in PBS/Tx100 0.4%, incubated one night at room temperature with the primary antibody and incubated with a biotinylated rabbit anti-goat antibody.
- the immunolabeling was revealed after an incubation with streptavidine alexa 555 fluor and sections were coverslipped with Mowiol medium (Calbiochem, USA) to be viewed under confocal microscopy.
- GFP expression and immunocytochemistry were observed with an inverted Nikon TE-2000 laser scanning confocal microscope, equipped with a blue argon ion laser and a helium neon laser emitting monochromatic rays at 488 nm (green) and 543 nm (red), respectively. Slides were scanned serially using a water immersed ⁇ 20 objective. Each image was recorded in a separated channel (channel green for GFP and channel red for streptavidin 555) and overlayed to allow detection of colocalized fluorescent signals.
- ssAAV1, ssAAV9, scAAV1 or scAAV9 encoding the murine secreted alkaline phosphatase (mSEAP) under the cytomegalovirus (CMV) promoter were injected into both triceps and gastrocnemius muscles in one day old C57Bl6 mice (8.10+9 to 2.10+10 viral genome per mouse, 3 mice per group).
- CMV cytomegalovirus
- the mSEAP expression was detected in the injected muscles 3 and 7 days after injection of each AAV serotype, except with ssAAV9, the expressing level dramatically increasing with time ( FIG. 1 a ).
- transgene expression was detected only after i.m. injection of scAAV9.
- the mSEAP expression was detected in the epithelial cells of the choroids plexus ( FIG. 1 b ), which have a crucial role in the secretion and the clearance of many proteins and toxins in the cerebrospinal fluid (CSF) (Redzic, 2005).
- the mSEAP expression in the choroids plexus was found as soon as 3 days post-injection (PN4), and the expression levels again increased with time.
- PN4 3 days post-injection
- a low level of mSEAP expression was detected in the diaphragm muscle fibres of mice injected with ssAAV1 by 3 days post-injection, which was similar to that observed with scAAV1 ( FIG. 2 a ), and with both vectors at 7 days after injection. ( FIG. 2 a ).
- SsAAV9 transduce a few muscle fibres only at 21 days post injection, whereas an intense mSEAP staining was found in the diaphragm when using scAAV9 from 3 days post-injection ( FIG. 2 a ). This high level of transduction was also observed in other muscles such as the triceps brachii or gastrocnemius muscle (data not shown).
- FIG. 2 b The epithelial cells of the choroids plexus and the ependyma appeared clearly labelled after injection with scAAV9 ( FIG. 2 b ). A robust transduction was further observed in these regions at 7 days post-injection ( FIG. 2 b ). Transgene expression was also observed within the meninges and blood vessels at 7 days post-injection, both in the brain and throughout the spinal cord, and was higher than that observed after i.m. injection ( FIG. 2 c ). Interestingly, mSEAP expression was also detected in some neural cells in the brain and the spinal cord ( FIG. 2 d ). Taken together, these results indicate that i.m. or i.p. injected scAAV9 vectors that express the mSEAP protein can efficiently target the CNS, especially the epithelial cells of the choroids plexus and the ependyma.
- mSEAP is a secreted protein
- the transgene expression observed in the CNS cells after peripheral AAV injection could result from protein transcytosis rather than from AAV cell transduction. We thus verified whether similar results could be obtained when using a non-secreted protein.
- a recombinant scAAV9 vector expressing the “green fluorescent protein” (GFP) was injected in neonatal mice either intraperitoneally (3.10+10 vg per mouse, 100 ⁇ l) or intramuscularly (8.10+9 vg in 20 ⁇ l per mouse, 5 ⁇ l per muscle). Seven days later, and similarly to that observed with scAAV9-mSEAP, the GFP expression was observed in the choroids plexus and ependyma cells located in the brain ventricles ( FIG. 3 a and FIG. 4 a ). Furthermore, we found in this case many GFP-positive neural cells in several brain regions located, in particular, close to the ventricles. Cell bodies and fibres in the hippocampus ( FIG. 3 b ), the septum ( FIG. 4 b,c ) and the entorhinal cortex ( FIG. 3 c , FIG. 4 d - e ) appeared efficiently transduced.
- GFP green fluorescent protein
- GFP expression was detected in cells of the spinal cord at 7 days after AAV administration, including in cells with a motor neuron-like phenotype ( FIG. 3 d,e ).
- a strong GFP expression was also found in fibres of the corticospinal tract that cross at the cervical spinal cord level ( FIGS. 3 f and 4 h ). Transduction of these fibres likely results from targeting of the upper MNs whose somas are located in the motor cortex and which also appeared GFP-immunopositive ( FIG. 3 d ).
- a higher number of GFP-immunopositive cells were detected in the CNS after i.p. than after i.m. injection, due to either the difference of efficacy between the routes of injection or to the higher titre of vector used in the i.p. procedure.
- GFP-expressing scAAV9 vectors were thus injected into the temporal vein of one day old C57Bl6 mice (50 ⁇ l, 1.5 ⁇ 10 +1 ° viral genome per mouse) and the CNS tissues were removed and processed for immunostaining 7 days thereafter.
- a strong GFP expression was detected in both the choroids plexus and ependyma cells ( FIG. 5 a ) and in the brain blood vessels ( FIG. 5 c ).
- GFP expression within cells of both neuron-like and glial-like phenotype throughout the brain, in particular in the entorhinal cortex ( FIG. 5 d ) and the hippocampus ( FIG. 5 e,f ).
- ssAAV9 could also cross the BBB and transduce the CNS cells after i.v. delivery, or if this property is specific to the double-stranded genome.
- GFP-expressing ssAAV9 vectors were injected into the temporal vein of neonatal mice and GFP expression was analyzed 3 weeks after (in order to permit genome conversion into double-stranded DNA).
- ssAAV9-GFP proved to mediate CNS cell transduction after i.v. delivery, although its efficacy was lower than that of scAAV9.
- the choroids plexus and ependyma cells expressed large amounts of GFP and many brain regions close to the cerebral ventricles were found to be transduced ( FIG. 6 a ).
- GFP-positive neurons were detected in the hippocampus and the habenular nuclei ( FIG. 6 a ) and in the median eminence ( FIG. 6 b ).
- some motor neuron-like cells were found to express GFP in the ventral spinal cord ( FIG. 6 c - e ).
- a few CNS cells were also found to express GFP after i.m. or i.p. delivery of the recombinant ssAAV9 (data not shown).
- FIG. 8 a - g there were many mSEAP-positive cells and fibers throughout the spinal cord after i.v. delivery of recombinant serotype 9 AAV vectors. Again, a higher level of transgene expression was observed with the sc—than with the conventional ssAAV9 vector ( FIG. 8 a,b versus 8 c - g ).
- scAAV9-GFP Similar injections using scAAV9-GFP demonstrated the superiority of scAAV9 for systemic gene delivery to the spinal cord. A high number of was found to express four weeks after i.v. injection of 2 ⁇ 10 12 vg scAAV9, GFP was expressed in the spinal cord in both neuronal and glial cells, as demonstrated using immunostaining of the glial fibrillary acidic protein (GFAP), a marker of astrocytes ( FIG. 11 ).
- GFAP glial fibrillary acidic protein
- FIG. 9 a A strong GFP signal was observed along the spinal cord from the cervical part to the cauda equina both in the gray and white matter, the expression pattern appearing similar in both the heterozygous and affected animals. Nerve fibers of the fasciculi gracilis and cuneatus dorsal sensory tracts expressed high levels of GFP ( FIG. 9 a ). Moreover, GFP expression was detected in a number of cell bodies in the ventral spinal cord, after both observation of GFP fluorescence ( FIG. 9 a,c ) and immunohistochemical analysis ( FIG. 9 b - d ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Abstract
Description
- The present invention relates to compositions and methods for delivering genes to cells of the central nervous system in mammals. The invention also relates to methods of treating motor neuron disorders in mammals by expression of therapeutic genes. The invention stems from the unexpected discovery that peripheral injection of AAV vectors leads to a bypass of the blood brain barrier and a massive infection of motor neurons, as well as other cells in the central nervous system. The invention may be used in any mammal, including human subjects.
- Motor neuron (MN) diseases, such as spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) or Kennedy's disease, are neurodegenerative disorders characterised by the selective degeneration of MNs in the spinal cord, brainstem and/or motor cortex (Monani 2005; Pasinelli and Brown 2006); (MacLean, Warne et al. 1996). There is no treatment for these diseases, mostly because drug delivery to MN via systemic injections is hindered by the presence of the “blood-brain-barrier” (BBB). This anatomical and physiological barrier is formed by tight junctions between the endothelial cells of the central nervous system (CNS) capillaries and prevents easy passage of molecules between the circulation and the CNS (Scherrmann 2002). The alternative supply of MN with recombinant proteins injected directly into the CNS parenchyma is also difficult due to the invasiveness of the surgical procedure hampering a potential clinical application.
- Failure of the classical pharmacology has led the scientific community to develop new therapeutic strategies based, in particular, on gene transfer technology using viral vectors. However, conventional viral vectors generally do not pass the BBB, and the first proposed gene transfer strategies included intrathecal delivery or direct injections of the vectors into the spinal cord parenchyma (Davidson, PNAS 2000) (Azzouz, Hottinger et al. 2000). However, these invasive approaches failed to produce efficient widespread CNS transduction. Injection of the viral vectors into the cerebral ventricles was also used in the aim to transduce the epithelial cells of the choroids plexus and ependyma, mediating secretion of the therapeutic proteins in the cerebrospinal fluid (CSF) and further diffusion through the CNS parenchyma (Passini and Wolfe 2001). However, diffusion of the recombinant proteins to the whole nervous tissue was far from being optimal, and again, the potential risks related to the surgical procedure is an obstacle to the clinical application of this method. An alternative non-invasive strategy was further developed using retrograde axonal transport of viral vectors to MN through intramuscular (i.m.) injections. Gene vectors such as adenovirus, adeno-associated vector (AAV) or equine-anemia viruses pseudotyped with the rabies G glycoprotein (EIAV) indeed undergo retrograde transport along the MN axons after i.m. injections, and were successfully used to transduce lower MN in experimental animals (Finiels et al., 1995; Kaspar et al., 2003; Azzouz et al., 2004). However, the clinical value of this method remains questionable due, in particular, to the large number of both injection sites and viral particles that would be needed for targeting MN in pathologies that affect most of the patient's motor units.
- In order to counteract these difficulties, we tested the efficiency for MN transduction of new AAV serotypes and genomes after intramuscular (i.m.), intravenous (i.v.) and intraperitoneal (i.p.) delivery in mice. In particular, we compared the efficiency of recombinant single-stranded and self-complementary AAV vectors (ssAAV and scAAV, respectively) of
serotype 1 and 9 for mediating CNS transduction in mice. - Our main results demonstrate that recombinant AAV vectors (e.g., scAAV9) are particularly efficient to transduce spinal cord MNs after i.v. delivery in mice. Furthermore, we show the feasibility of this method in a large animal model, a domestic cat model of autosomal recessive SMA similar to human SMA type III, associated to deletions of the LIX1 gene (Fyfe et al, 2006). Our method also allows to transduce other cells of the CNS, including glial cells, neurons in the hippocampus and habenular nuclei, and astrocytes. This invention thus shows, for the first time, that it is possible to transfer genes of interest to MNs after a single i.v. injection in mice, achieving broad gene delivery to the spinal cord and/or other nervous cells, therefore, offering new avenues for the treatment of MN diseases.
- The present invention relates to novel compositions and methods for the delivery of therapeutic products to the CNS using recombinant AAV vectors. More specifically, the invention relates to compositions and methods for delivering genes into the motor neurons or glial cells of mammalian subjects through peripheral administration of AAV vectors.
- An object of this invention more specifically relates to the use of an AAV vector comprising a gene of interest (e.g., encoding a therapeutic or diagnostic product) for the manufacture of a medicament for delivering the gene to cells in the central nervous system, particularly motor neurons or glial cells, by peripheral administration of said AAV vector to said subject.
- An other object of this invention relates to the use of an AAV vector comprising a gene of interest (e.g., encoding a therapeutic or diagnostic product) for the manufacture of a medicament for delivering the gene to spinal cord motor neurons by peripheral administration of said AAV vector to said subject.
- A further object of this invention resides in a method of delivering a gene to cells in the central nervous system, particularly motor neurons or glial cells, in a mammal, the method comprising administering to the mammal by peripheral route an AAV vector comprising said gene, said administration allowing infection of cells in the central nervous system, particularly motor neurons or glial cells, by said AAV vectors and thereby delivery of said gene to cells in the central nervous system, particularly motor neurons or glial cells.
- An object of this invention also relates to the use of an AAV vector comprising a therapeutic gene for the manufacture of a medicament for treating a motor neuron disorder in a subject, wherein said AAV vector is administered by peripheral injection to said subject, said administration causing infection of (spinal cord) motor neurons and expression of the gene in (spinal cord) motor neurons.
- Another object of this invention relates to the use of an AAV vector for the manufacture of a medicament for producing a therapeutic protein or RNA into (spinal cord) motor neurons of a subject by peripheral injection of said vector.
- The invention also relates to the use of an AAV vector for delivering a gene to cells in the central nervous system, particularly motor neurons or glial cells, by crossing the blood brain barrier.
- The invention also relates to a method of gene therapy across the blood brain barrier in a mammalian subject, the method comprising the peripheral administration of an AAV vector to the subject.
- A further object of this invention is a method of genetically modifying cells in the central nervous system, particularly motor neurons in a mammalian subject, the method comprising peripherally administering AAV vectors to the subject.
- The invention also relates to the use of an AAV vector for the manufacture of a medicament for delivering a gene to the spinal cord by peripheral administration of the AAV vector.
- The invention also resides in a method of gene delivery to the spinal cord of a subject, the method comprising peripherally administering to the subject an AAV vector comprising said gene.
-
FIG. 1a-c . Widespread gene delivery to the neonatal mouse muscles and CNS after intramuscular AAV injection (blue: mSEAP histochemical staining). Representative cross sections of the (a) gastrocnemius muscle (b) brain (3rd ventricle) and (c) spinal cord at 3 days (PN4) or 7 days (PN8) after injection of ss- or scAAV1 or AAV9. -
- NI: non-injected; PN4, post-natal 4; PN8, post-natal 8; ss, single-strand; sc: self-complementary. Scale bar (b, c) 100 μm.
-
FIG. 2a-d . Widespread gene delivery to the neonatal mouse muscles and CNS after intraperitoneal AAV injection (blue: mSEAP histochemical staining). Representative tissue sections of the (a) diaphragm muscle (b) cerebral 3rd ventricle (arrows: mSEAP expressing choroids plexus cells; arrowheads: ependymal cells) (c) CNS parenchyma (arrows: neuronal cells). -
- NI: non-injected; PN4, post-natal 4; PN8, post-natal 8; ss, single-strand; sc: self-complementary. Scale bar (a, b, c) 100 μm; (d) 40 μm.
-
FIG. 3a-h . Intraperitoneal delivery of self-complementary AA9-GFP mediates CNS transduction in neonatal mice. Representative brain and spinal cord cross sections treated for GFP immunohistochemistry 7 days after AAV delivery. Transgene expression was detected in (a) the choroids plexus epithelial cells (b) hippocampal cells with a neuronal (arrowhead and top box) and glial (arrow and bottom box) morphology (c) cells of the entorhinal cortex (arrows indicate cells with a typical neuronal morphology) (d, e) cells of the spinal cord (the arrow indicates a GFP-labelled cell with a motor neuron morphology) and (f) sensory fibers in the cervical spinal cord. Scale bar 40 μm. -
FIG. 4a-f . Intramuscular delivery of self-complementary AAV9 vectors allows transduction of CNS cells in neonatal mice. Brain and spinal cord histological sections were treated with GFP immunohistochemistry 7 days after AAV injection. Transgene expression was detected in (a) the epithelial cells of the choroids plexus (arrow) and the ependyma (arrowheads) (b,c) neural cells of the septum and (d, e) of the entorhinal cortex and (f) the corticospinal tract at the level of the pyramidal decussation in the cervical spinal cord (arrows). Scale bar 20 μm. -
FIG. 5a-m . Intravenous delivery of self-complementary AAV9 vectors mediate GFP expression in the CNS of neonatal mice. Representative photomicrographs of brain and spinal cord histological sections treated for GFP immunostaining 7 days after AAV injection. GFP-positive cells were detected in (a) the epithelial cells of the choroids plexus (arrow) and the ependyma (arrowheads) (c) brain blood vessels (d,f) hippocampal cells with a neuronal (arrow) and glial (arrowhead) morphology (g) neuron-like cells of the entorhinal cortex. Many motor neuron-like cell bodies (arrows) and fibres (arrowheads) were efficiently transduced throughout the spinal cord at the (h) cervical (i) thoracic and (j) lumbar levels. No staining was observed in the CNS of uninjected mice as shown in representative sections from (b) the 3rd ventricle or (e) the hippocampus or (k-m) the spinal cord. Scale bar (a, b) 100 μm, (c, d, f) 40 μm, (e, g) 100 μm, (h-m) 20 μm. -
FIG. 6a-e . GFP-expressing single-stranded AAV9 vectors mediate transgene expression in the CNS of neonatal mice. Representative photomicrographs of brain and spinal cord sections from neonatal mice treated for GFP-immunohistochemistry 3 weeks after i.v. injection of ssAAV9 vectors. GFP-positive cells in (a) the choroids plexus (asterisk), the hippocampus (arrowhead and box) and the habenular nucleus (arrow) (b) the median eminence and (c-e) motor neuron-like cells in the ventral spinal cord. Scale bar panels b: 100 μm; c, d, e: 20 μm. -
FIG. 7a-h . Recombinant AAV9 vectors mediate transgene expression in the adult mouse CNS. Representative coronal brain sections from adult C57bl6 mice 4 weeks after intravenous delivery of 3×1011 (b) or 1×1012 (c-h) vector genome of mSEAP-expressing scAAV9 (a,c), ssAAV9 (b), scAAV1 (d) and ssAAV1 (e); Scale bar panels g, h, j: 100 μm; panels i, k, l: 20 μm. -
FIG. 8a-g . Intravenously injected recombinant AAV9 vectors mediate transgene expression in the spinal cord of adult mice. Representative transversal spinal cord sections from adult C57bl6 mice 4 weeks after intravenous delivery of 1×1012 vector genome of mSEAP-expressing ssAAV9 (a,b), scAAV9 (c,g). Scale bars (a,b,e): 40 μm, boxes: 20 μm; (c,d): 100 μm; (f): 50 μm; (g): 20 μm. -
FIG. 9a-d . Intravenous injection of AAV9-GFP in LIX-1 cats mediates transgene expression throughout the spinal cord. Representative transversal spinal cord sections from a 2 days-old LIX1 heterozygous cat were observed using laser scanning confocal microscopy (FIG. 9a,c ) or treated for GFP immunohistochemistry (FIG. 9b,d ) 10 days after injection of GFP-expressing scAAV9 into the jugular vein. -
- Scale bars (a): 200 μm; (b, d): 50 μm; (c): 100 μm.
-
FIG. 10a-f . Intravenous injection of GFP expressing AAV9 (1.5×10+12 vector genome-containing particles of scAAV9-CMV-eGFP) in LIX-1 cats mediates transgene expression in motor neurons. A double-immunostaining analysis using antibodies against GFP and choline acetyl transferase (ChAT) showed that, in both SMA-affected (a-c) and non-affected kitten (d-f), a significant part of the GFP-positive cells were motor neurons. -
FIG. 11a-l . Widespread spinal cord transduction is mediated by i.v. delivery of highly concentrated scAAV9 in adult mice. - High GFP expression in neuronal (arrows) and glial (arrowheads) cells in (a-c) cervical and (d,e) lumbar spinal cord (f) dorsal root ganglion sections treated for GFP-immunostaining 4 weeks after i.v. injection of 2×1012 vg scAAV9. (g-l) Double immunofluorescence analysis for (g, j) GFP and (h, k) GFAP (glial fibrillary acidic protein, a marker of astrocytes, red) shows GFP expression in some astrocytes (arrowheads indicate double-labeled cells). (i, l) Merge. Scale bars (a, b, d-l): 50 μm, (c): 20 μm.
- Widespread gene delivery to the spinal cord is an important challenge for the treatment of motor neuron (MN) diseases such as spinal muscular atrophy (SMA) or amyotrophic lateral sclerosis (ALS). Here, we describe a new gene transfer methodology that allows efficient MN transduction after a single peripheral injection of recombinant AAV vectors. We injected recombinant single strand (ss) and self-complementary (sc) AAV vectors of
serotype 1 and 9 intraperitonealy, intramuscularly or intravenously (i.v.) in neonatal or adult mice and analyzed transgene expression in the central nervous system (CNS). Both recombinant ss- and scAAV9 vectors were found to target neural and epithelial brain cells and, importantly, motor neurons and glial cells in the spinal cord. The dorsal sensory fibers and the dorsal root ganglions also appeared highly transduced. The most impressive transduction efficacy was obtained with i.v. injected scAAV9 vectors. We further confirmed the ability of i.v. injected scAAV9 to bypass the blood-brain barrier and transduce lower motor neurons in a feline model of SMA. This strategy represents the first non invasive procedure that achieves widespread transgene delivery to the spinal cord, offering new avenues for the treatment of MN diseases. - AAV Vectors
- Within the context of the present invention, the term “AAV vector” designates any vector which comprises or derives from components of AAV and is suitable to infect mammalian cells, preferably human cells. The term AAV vector typically designates an AAV type viral particle (or virion) comprising at least a nucleic acid molecule encoding a therapeutic protein. As will be discussed below, the AAV may be derived from various serotypes, including combinations of serotypes (i.e., “pseudotyped” AAV) or from various genomes (e.g. single-stranded or self-complementary). In addition, the AAV vector may be replication defective and/or targeted.
- Adeno-associated virus (AAV) is a dependent parvovirus, of approximately twenty nanometers in size. Like other parvoviruses, AAV is a single-stranded, non-enveloped DNA virus, having a genome of about 5000 nucleotides in length, containing two open reading frames. The left-hand open reading frame codes for the proteins responsible for replication (Rep), while the right-hand open reading frame encodes the structural proteins of the capsid (Cap). The open reading frames are flanked by two ITR sequences, which serve as the origin of replication of the viral genome. Furthermore, the genome also contains a packaging sequence, allowing packaging of the viral genome into an AAV capsid.
- AAV requires co-helper functions (which may be provided e.g. by an adenovirus, or by suitable packaging cells or helper plasmids) to undergo a productive infection in cultured cells. In the absence of such helper functions, the AAV virions essentially enter the cells, migrate to the nucleus as a single-stranded DNA molecule, and integrate into the cells' genome. AAV has a broad host range for infectivity, including human cells, is ubiquitous in humans, and is completely non-pathogenic.
- AAV vectors have been designed, produced and used to mediate gene delivery in human subjects, including for therapeutic purposes. Clinical trials are presently ongoing in various countries using AAV vectors. Typically, AAV vectors for use in gene transfer comprise a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. Such replication defective AAV vectors more preferably lack most or all of the Rep and Cap coding sequences, and essentially retain one or two AAV ITR sequences and a packaging sequence.
- Methods of producing such AAV vectors have been disclosed in the literature, including using packaging cells, auxiliary viruses or plasmids, and/or baculovirus systems (Samulski et al., (1989) J. Virology 63, 3822; Xiao et al., (1998) J. Virology 72, 2224; Inoue et al., (1998) J. Virol. 72, 7024; WO98/22607; WO2005/072364). Methods of producing pseudotyped AAV vectors have also been reported (e.g., WO00/28004), as well as various modifications or formulations of AAV vectors, to reduce their immunogenicity upon in vivo administration (see e.g., WO01/23001; WO00/73316; WO04/112727; WO05/005610; WO99/06562).
- AAV vectors may be prepared or derived from various serotypes of AAVs, which may be even mixed together or with other types of viruses to produce chimeric (e.g. pseudotyped) AAV viruses.
- In a particular embodiment, the AAV vector for use in the present invention is derived from a human AAV virus.
- Such a human AAV (capsid and ITR) may be derived from any known serotype, e.g. from any one of serotypes 1-11, preferably from AAV2, AAV4, AAV6, AAV8 and AAV9, more preferably from AAV6, AAV8 and AAV9, even more preferably from AAV9. Specific examples of such AAV vectors are vectors comprising an AAV2-derived genome (a nucleic acid molecule comprising an AAV2-derived ITR and an AAV2-derived packaging sequence, operatively linked to a nucleic acid encoding a therapeutic protein, preferably two AAV2-derived ITR flanking an AAV2-derived packaging sequence and a nucleic acid encoding a therapeutic protein) in an AAV2-derived capsid; vectors comprising an AAV4-derived genome in an AAV4-derived capsid; vectors comprising an AAV6-derived genome in an AAV6-derived capsid; vectors comprising an AAV8-derived genome in an AAV8-derived capsid; vectors comprising an AAV9-derived genome in an AAV9-derived capsid
- In another particular embodiment, the AAV vector is a pseudotyped AAV vector, i.e. comprises sequences or components originating from at least two distinct AAV serotypes. In a particular embodiment, the pseudotyped AAV vector comprises an AAV genome derived from one AAV serotype (for example AAV2), and a capsid derived at least in part from a distinct AAV serotype. Specific examples of such pseudotyped AAV vectors include, without limitation, vectors comprising an AAV2-derived genome in an AAV4-derived capsid; or vectors comprising an AAV2-derived genome in an AAV6-derived capsid; or vectors comprising an AAV2-derived genome in an AAV8-derived capsid; or vectors comprising an AAV2-derived genome in an AAV9-derived capsid;
- In a further particular embodiment, which may be combined with any of the above embodiments, the AAV vector may comprise a modified capsid, including proteins or peptides of non viral origin or structurally modified, to alter the tropism of the vector. As a particular example, the capsid may include a ligand of a particular receptor, or a receptor of a particular ligand, to target the vector towards cell type(s) expressing said receptor or ligand, respectively.
- In the AAV vectors used in the present invention, the AAV genome may be either a single stranded nucleic acid or a double stranded, self complementary nucleic acid (McCarty et al., Gene Therapy, 2001), more preferably a self complementary nucleic acid.
- As discussed above, the AAV-derived genome comprises a nucleic acid encoding a therapeutic protein. Typically, the nucleic acid also comprises regulatory sequences allowing expression and, preferably, secretion of the encoded protein, such as e.g., a promoter, enhancer, polyadenylation signal, internal ribosome entry sites (IRES), sequences encoding protein transduction domains (PTD), and the like. In this regard, the nucleic acid most preferably comprises a promoter region, operably linked to the coding sequence, to cause or improve expression of the therapeutic protein in infected cells. Such a promoter may be ubiquitous, tissue-specific, strong, weak, regulated, chimeric, etc., to allow efficient and suitable production of the protein in the infected tissue. The promoter may be homologous to the encoded protein, or heterologous, including cellular, viral, fungal, plant or synthetic promoters. Most preferred promoters for use in the present invention shall be functional in nervous cells, particularly in human cells, more preferably in motor neurons. Examples of such regulated promoters include, without limitation, Tet on/off element-containing promoters, rapamycin-inducible promoters and metallothionein promoters. Examples of promoters specific for the motor neurons include the promoter of the Calcitonin Gene-Related Peptide (CGRP), a known motor neuron-derived factor. Other promoters functional in motor neurons include the promoters of Choline Acetyl Transferase (ChAT), Neuron Specific Enolase (NSE), Synapsin, or ubiquitous promoters including Neuron Specific Silencer Elements (NRSE). Examples of ubiquitous promoters include viral promoters, particularly the CMV promoter, the RSV promoter, the SV40 promoter, etc. and cellular promoters such as the PGK (phosphoglycerate kinase) promoter.
- In a preferred embodiment, the nucleic acid comprises a leader sequence allowing secretion of the encoded protein. Fusion of the transgene of interest with a sequence encoding a secretion signal peptide (usually located at the N-terminal of secreted polypeptides) will allow the production of the therapeutic protein in a form that can be secreted from the transduced cell into the CSF. Examples of such signal peptides include the albumin, the 3-glucuronidase, the alkaline protease or the fibronectin secretory signal peptides.
- According to another specific embodiment, the transgene is fused with PTD sequences, such as the Tat or VP22 sequences, in order to cause or improve secretion of the therapeutic protein from the transduced cells and re-uptake by neighbour ones.
- In a particular embodiment the nucleic acid comprises, operably linker, a promoter and a leader sequence, to allow expression and secretion of the encoded protein.
- In a further particular embodiment, the nucleic acid comprises, operably linker, a promoter, a leader sequence and a PTD sequence, to allow expression and secretion of the encoded protein.
- In a most preferred embodiment, the promoter is specific or functional in motor neurons, i.e., allows (preferential) expression of the transgene in said cells.
- As discussed above, the AAV vectors may be produced by techniques known per se in the art, as further illustrated in the examples.
- Peripheral Administration
- The invention is based on the unexpected discovery that effective and widespread expression of genes into motor neurons or glial cells can be achieved with non-invasive techniques, through peripheral administration of AAV vectors. Such peripheral administration includes, without limitation, any administration route which does not imply direct injection into the brain. More particularly, peripheral administration comprises systemic injections, such as intramuscular (i.m.), intravenous (i.v.), intraperitoneal (i.p.), intra-arterial, sub-cutaneous or transdermic injections. Peripheral administration also includes oral administration of AAV vectors (WO96/40954), delivery using implants (WO01/91803), or administration by instillation through the respiratory system, e.g., using sprays, aerosols or any other appropriate formulations.
- Most preferred peripheral administration includes peripheral injection, in particular systemic injection, most preferably i.m., i.p. or i.v. injection. The doses of AAV vectors may be easily adapted by the skilled artisan, e.g., depending on the disease condition, the subject, the treatment schedule, etc. Typically, from 109 to 1014 viral genomes (transducing units) are administered per dose in mice, preferably from about 1011 to 1013.
- Typically, the doses of AAV vectors to be administered in humans may range from 1011 to 1017 viral genomes, preferably from 1013 to 1016.
- A preferred effective dose within the context of this invention is a dose allowing an optimal transduction of the spinal cord cells (motor neurons and/or glial cells).
- The AAV vector may be administered in any suitable form, either as a liquid solution or suspension, as a solid form suitable for solution or suspension in liquid prior to injection, as a gel or as an emulsion. The AAV vectors are typically formulated with any appropriate and pharmaceutically acceptable excipient, carrier, adjuvant, diluent, etc. For injection, the excipient may be a liquid, isotonic solution, buffer, such as a sterile and pyrogen-free water or a sterile and pyrogen-free phosphate-buffered saline solution. For inhalation, the excipient may be in particulate form.
- The AAV vectors are typically administered in a “therapeutically-effective” amount, i.e., an amount that is sufficient to alleviate (e.g., decrease, reduce) at least one of the symptoms associated with the disease state, or to provide improvement in the condition of the subject. It should be pointed out that repeated administrations may be performed, if required, using either the same or different peripheral administration route and/or the same or distinct AAV serotypes.
- The inventors have shown for the first time that AAV vectors, in particular scAAV vectors, administered peripherally cross the blood brain barrier and cause substantial infection of CNS cells. This effect is obtained without the need of using blood-brain barrier disrupting agents. Hyperthermia, mannitol, bradykinin and NS1619 are illustrative blood-brain barrier disrupting agents.
- Accordingly, in a particular embodiment, the invention relates to an use or method as defined above, comprising peripheral administration of an AAV vector, preferably a scAAV vector, more preferably a scAAV9 vector, wherein no blood-brain barrier disrupting agent is implemented. Furthermore, the invention relates to an use or method as defined above, wherein no mannitol is injected to the subject.
- Alternatively, in another particular embodiment, the invention relates to an use or method as defined above, further comprising disruption of the blood-brain barrier with a blood-brain barrier disrupting agent or process, to further increase the crossing of the scAAV vectors implemented in the present invention through the blood-brain barrier.
- Motor Neuron Disorder
- The invention shows, for the first time, that AAV vectors administered peripherally cross the blood brain barrier and cause substantial infection of CNS cells, particularly of motor neurons throughout the spinal cord. The results presented show that infection is effective from the cervical segment to the lumbar segment of the spinal cord, thereby providing a widespread gene delivery into motor neurons.
- The invention may be used to treat a variety of disorders through delivery of a therapeutic product into CNS cells including the motor neurons. The therapeutic product may be any protein, peptide or RNA that may alleviate or reduce symptoms that result from an absence or defect in a protein in a cell or subject or that otherwise confers a benefit to a subject. Examples of therapeutic proteins include growth factors, cytokines, hormones, neurotransmitters, enzymes, anti-apoptotic factors, angiogenic factors, and any protein known to be mutated in pathological disorders such as the “survival of motor neuron” protein (SMN). Examples of therapeutic RNA include antisense RNA or RNAi targeting messenger RNAs coding for proteins having a therapeutic interest in any of the diseases mentioned herein below. For example, an RNAi targeting the superoxide dismutase enzyme may be coded by an AAV vector as defined above, in view of the treatment of ALS.
- Depending on the therapeutic product, the invention can be used to treat various diseases, including any disease which may be treated or prevented by expressing therapeutic proteins into nervous tissue. Such diseases include CNS disorders, preferably selected from neurodegenerative diseases, neuromuscular diseases, lysosomal diseases, trauma, bone marrow injuries, pain (including neuropathic pain), cancers of the nervous system, demyelinating diseases, autoimmune diseases of the nervous system, neurotoxic syndromes, sleeping disorders.
- Specific examples of diseases include Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, Sly disease, Hunter's disease, dementia, paranoia, obsessive compulsive disorder, learning disabilities, amyotrophic lateral sclerosis, spinal muscular atrophy, Charcot-Marie Tooth disease, spinocerebellar ataxia, spastic paraplegia, Kennedy's disease, glioblastoma, neuroblastoma, autism, Gaucher's disease, Hurler's disease, Krabbe's disease and altered behaviors (e. g., disorders in sleeping, perception or cognition).
- The invention may be used in any mammalian, particularly in human subjects, including adults, for preventive or curative treatment.
- The invention can also be used in diagnostic methods, to detect the status or activity or growth of motor neurons in mammalian subjects. For such indications, the vector typically comprises a detectable gene (fluorescent, luminescent, etc.) and is used as a marker.
- The invention can also be used in animal subjects, e.g., to assist in the research of candidate drugs for treating CNS disorders and/or to understand the mechanisms of motor neuron growth, differentiation, activity, etc.
- Further aspects and advantages of the present inventions will be disclosed in the following experimental section, which shall be considered as illustrative only, and not limiting the scope of this application.
- Material and Methods
- Animals.
- Pregnant and adult (six to eight week old, female) C57Bl/6 mice were purchased from Charles River Laboratories (Les Oncins, France). Neonates were injected on the day of birth (post-natal 1, PN1). SMA cat breeders (heterozygous and affected animals) were obtained from Dr. Fyfe (Laboratory of Comparative Medical Genetics, Michigan, US) and housed in the Center of Boisbonne at the Nantes Veterinary School. Genotyping of SMA kittens was performed as described previously (Fyfe, Menotti-Raymond et al. 2006). Experiments were approved by the regional ethic committee (CREEA).
- All animal experiments were carried out according to the European guidelines for the human care and use of experimental animals.
- Vector Preparation.
- Pseudotyped AAV2/1 and AAV2/9 vectors were generated by packaging AAV2_based recombinant single-stranded (ss) and self-complementary (sc) genomes in AAV1 and 9 capsids. Briefly, the vectors were produced using a helper-virus free three-plasmid transfection in HEK293 cells with (1) the adenovirus helper plasmid (2) the AAV packaging plasmid encoding the rep2 and cap1 or 9 genes (pLTRCO2 for AAV1 and p5E18-VD2/9 for AAV9) (3) the AAV2 vector plasmid containing mSeAP or GFP (under control of the cytomegalovirus immediate early (CMV IE) promoter) as ss or sc genome (Xiao, Li et al. 1998). This latter plasmid was constructed by deleting the D sequence and the terminal resolution site (trs) site from one of the inverted terminal repeat. The recombinant vectors were purified by double-CsCl ultracentrifugation followed by dialysis against phosphate-buffered saline. Physical particles were quantified by real time PCR for vectors injected in mice and by dot blot hybridisation for vectors injected in kittens and the vectors titers were expressed as viral genome per milliliter (vg/ml).
- In Vivo Injection of the AAV Vectors
- Neonates mice were injected on the day of birth (post natal 1, PN1). For i.m. injections, AAV vector solutions (ssAAV2/1 (n=2), ssAAV2/9 (n=2), scAAV2/1 (n=2) or scAAV2/9 (n=3) encoding mSeAP or GFP were injected into both triceps and gastrocnemius muscles (1 injection site per muscle, 5 μl per injection, 8×10+9 to 2×10+10 viral genome per mouse). For i.p. injections, the viral solutions (ssAAV2/1, n=2, ssAAV2/9, n=1, scAAV2/1, n=1 and scAAV2/9, n=2) encoding mSeAP or GFP were injected into the peritoneal cavity of one day old C57Bl/6 mice (100 μl, 3×10+10 to 10+11 viral genome per mouse). For i.v. injections, one day old C57Bl/6 mice were injected into the temporal vein with scAAV2/9-GFP vector (50 μl, 1.5×10+10 viral genome per mouse, n=3). Adult C57Bl/6 mice were injected into the tail vein with scAAV2/9-mSeAP or scAAV2/9-GFP vector (500 μl, 3×10+11 vg per mouse, n=3).
- At 2 days after birth, a total of 1.5×10+12 vector genome-containing particles of scAAV9-CMV-eGFP were injected into the jugular vein of one SMA-affected kitten and one SMA-heterozygous kitten.
- Perfusion and Tissue Processing for Histology
- Muscles, brains and spinal cords were removed at 1 (PN2), 3 (PN4) or 7 (PN8) days post-injection from neonate mice or 7 and 35 days post-injection from adult mice. Adult C57Bl6 mice were anesthetized (
xylazine 10 mg/kg, ketamine 100 mg/kg) and perfused intracardially with 0.1 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Tissues were removed and post-fixed for 4 h in the same solution before being transferred overnight at 4° C. into 15% sucrose for brains and muscles and 30% sucrose for the spinal cords. Neonates were decapitated and tissues were immersed in 4% PFA for 4 h before being cryoprotected overnight at 4° C. Samples were frozen in cold isopentane (−50° C.) and serial sections were cut in a cryostat and stored at −80° C. for further analysis. - At 10 days post-injection, kittens were anesthetized (medetomidine 150 μg/kg,
ketamine 10 mg/kg) and perfused transcardially with 10 ml of phosphate-buffered saline followed by 100 ml of 4% PFA. Brains and spinal cords were removed and cut into coronal 5 mm slabs then posffixed in 4% PFA following by overnight cryoprotection in 30% sucrose and then frozen on dry ice in OCT compound. Spinal cord slices were cut in intervalls of 1×100 μm followed by 5×10 μm in a cryostat. Hundred μm-thick sections were used for examination of GFP signal by confocal microscopy, and 10 μm-thick sections were used for immunocytochemistry. - Evaluation of Transgene Expression
- For mSeAP histochemistry, muscles, brains and spinal cords from neonate mice were removed at 1, 3 and 7 days p.i., frozen in cold isopentane (−50° C.), and maintained at −80° C. for extemporal use. Brain and spinal cord from adult animals were harvested at 35 days p.i and treated under the same conditions. Tissue sections of 16 μm thick for brain and spinal cord, and 8 μm thick for muscles were performed in a cryostat and subsequently processed for transgene expression. The sections were fixed with 0.5% glutaraldehyde, washed with PBS and endogenous alkaline phosphatase was heat-inactivated for 30 min at 65° C. Sections were then incubated overnight at 37° C. in 0.165 mg/ml 5-bromo-4-chloro-3-indolylphosphate and 0.33 mg/ml of nitroblue tetrazolium in 100 mM Tris-HCl, 100 mM NaCl and 50 mM MgCl2, counterstained with hematoxylin-eosin, and mounted with Eukit.
- For GFP immunohistochemistry in mice, sections were washed in PBS and incubated for 30 min in a solution of hydrogen peroxide (Peroxydase-Blocking solution, Dako) for inhibition of the endogenous peroxidases. After washing in PBS, sections were blocked for one hour at room temperature in PBS with 10 goat serum (Dako) and 0.4% Triton and then incubated overnight with a rabbit polyclonal anti-GFP (Abcam; 1:3000). A biotin-conjugated secondary antibody (Vectastain, 1:200) and the Vectastain Elite ABC kit were used, and DAB staining was revealed with the DAB substrate kit for peroxydase (Vector Laboratories). Sections were dehydrated in alcohol and xylen, and mounted with Eukit.
- GFP immunocytochemistry in cat was realised on 10 μm spinal cord frozen sections. Briefly, spinal cord sections were permeabilized with 0.2% Tween 20 in PBS (pH 7.4), blocked with 5% goat serum, incubated two nights at 4° C. with polyclonal antibody AB3080 to GFP (Chemicon, 1:50) and incubated with a biotinylated goat anti-rabbit antibody. The immunolabeling was revealed after an incubation with the streptavidine-peroxydase complex by using the diaminobenzidine substrate peroxydase. The sections were counterstained with haematoxylin.
- Motor neuron's choline acetyltransferase was labeled with choline acetyltransferase (ChAT) goat polyclonal ChAT antibody (AB144P, Chemicon, France, 1:100). Briefly, spinal cord sections were blocked with 1% rabbit serum in PBS/Tx100 0.4%, incubated one night at room temperature with the primary antibody and incubated with a biotinylated rabbit anti-goat antibody. The immunolabeling was revealed after an incubation with streptavidine alexa 555 fluor and sections were coverslipped with Mowiol medium (Calbiochem, USA) to be viewed under confocal microscopy.
- Laser Confocal Scanning Microscopy
- GFP expression and immunocytochemistry were observed with an inverted Nikon TE-2000 laser scanning confocal microscope, equipped with a blue argon ion laser and a helium neon laser emitting monochromatic rays at 488 nm (green) and 543 nm (red), respectively. Slides were scanned serially using a water immersed ×20 objective. Each image was recorded in a separated channel (channel green for GFP and channel red for streptavidin 555) and overlayed to allow detection of colocalized fluorescent signals.
- We first evaluated the potential of
serotype 1 and 9 ss- or scAAV vectors to transduce the CNS cells after i.m. injection. The ssAAV1, ssAAV9, scAAV1 or scAAV9 encoding the murine secreted alkaline phosphatase (mSEAP) under the cytomegalovirus (CMV) promoter were injected into both triceps and gastrocnemius muscles in one day old C57Bl6 mice (8.10+9 to 2.10+10 viral genome per mouse, 3 mice per group). The injected muscle, brain and spinal cord tissues were removed 1, 3 or 7 days post injection and analysed for mSEAP expression using histochemistry. - The mSEAP expression was detected in the injected muscles 3 and 7 days after injection of each AAV serotype, except with ssAAV9, the expressing level dramatically increasing with time (
FIG. 1a ). In the CNS, transgene expression was detected only after i.m. injection of scAAV9. Interestingly, the mSEAP expression was detected in the epithelial cells of the choroids plexus (FIG. 1b ), which have a crucial role in the secretion and the clearance of many proteins and toxins in the cerebrospinal fluid (CSF) (Redzic, 2005). The mSEAP expression in the choroids plexus was found as soon as 3 days post-injection (PN4), and the expression levels again increased with time. A weak transgene expression was also located in and around blood vessels of the brain and the spinal cord after i.m. injection of the scAAV9 vector (FIG. 1c ). - We then analysed whether i.p. administration of ssAAV1, ssAAV9, scAAV1 and scAAV9 in one day old C57Bl6 mice (100 μl, 3·10+10 to 1·10+11 viral genome per mouse) could mediate transgene expression in the CNS at 1, 3 or 7 days post injection.
- A low level of mSEAP expression was detected in the diaphragm muscle fibres of mice injected with ssAAV1 by 3 days post-injection, which was similar to that observed with scAAV1 (
FIG. 2a ), and with both vectors at 7 days after injection. (FIG. 2a ). SsAAV9 transduce a few muscle fibres only at 21 days post injection, whereas an intense mSEAP staining was found in the diaphragm when using scAAV9 from 3 days post-injection (FIG. 2a ). This high level of transduction was also observed in other muscles such as the triceps brachii or gastrocnemius muscle (data not shown). - The epithelial cells of the choroids plexus and the ependyma appeared clearly labelled after injection with scAAV9 (
FIG. 2b ). A robust transduction was further observed in these regions at 7 days post-injection (FIG. 2b ). Transgene expression was also observed within the meninges and blood vessels at 7 days post-injection, both in the brain and throughout the spinal cord, and was higher than that observed after i.m. injection (FIG. 2c ). Interestingly, mSEAP expression was also detected in some neural cells in the brain and the spinal cord (FIG. 2d ). Taken together, these results indicate that i.m. or i.p. injected scAAV9 vectors that express the mSEAP protein can efficiently target the CNS, especially the epithelial cells of the choroids plexus and the ependyma. - Since mSEAP is a secreted protein, the transgene expression observed in the CNS cells after peripheral AAV injection could result from protein transcytosis rather than from AAV cell transduction. We thus verified whether similar results could be obtained when using a non-secreted protein.
- A recombinant scAAV9 vector expressing the “green fluorescent protein” (GFP) was injected in neonatal mice either intraperitoneally (3.10+10 vg per mouse, 100 μl) or intramuscularly (8.10+9 vg in 20 μl per mouse, 5 μl per muscle). Seven days later, and similarly to that observed with scAAV9-mSEAP, the GFP expression was observed in the choroids plexus and ependyma cells located in the brain ventricles (
FIG. 3a andFIG. 4a ). Furthermore, we found in this case many GFP-positive neural cells in several brain regions located, in particular, close to the ventricles. Cell bodies and fibres in the hippocampus (FIG. 3b ), the septum (FIG. 4b,c ) and the entorhinal cortex (FIG. 3c ,FIG. 4d-e ) appeared efficiently transduced. - Importantly, GFP expression was detected in cells of the spinal cord at 7 days after AAV administration, including in cells with a motor neuron-like phenotype (
FIG. 3d,e ). A strong GFP expression was also found in fibres of the corticospinal tract that cross at the cervical spinal cord level (FIGS. 3f and 4h ). Transduction of these fibres likely results from targeting of the upper MNs whose somas are located in the motor cortex and which also appeared GFP-immunopositive (FIG. 3d ). Globally, a higher number of GFP-immunopositive cells were detected in the CNS after i.p. than after i.m. injection, due to either the difference of efficacy between the routes of injection or to the higher titre of vector used in the i.p. procedure. - Since recombinant scAAV9 vector appeared as the most efficient one for mediating CNS cell transduction after i.m or i.p delivery, we evaluated whether this could be improved by using the i.v. route of administration.
- GFP-expressing scAAV9 vectors were thus injected into the temporal vein of one day old C57Bl6 mice (50 μl, 1.5·10+1° viral genome per mouse) and the CNS tissues were removed and processed for immunostaining 7 days thereafter. A strong GFP expression was detected in both the choroids plexus and ependyma cells (
FIG. 5a ) and in the brain blood vessels (FIG. 5c ). Again, we found GFP expression within cells of both neuron-like and glial-like phenotype throughout the brain, in particular in the entorhinal cortex (FIG. 5d ) and the hippocampus (FIG. 5e,f ). - A very high level of transgene expression was found throughout the spinal cord (from the cervical to the lumbar segments) in cells with a motor neuron-like phenotype and location (ventral spinal cord) (
FIG. 5h-i ). This probably results from diffusion of the vector through the blood vessels from the circulation to the brain parenchyma, or/and to axonal anterograde transport from upper CNS regions. - We then determine whether ssAAV9 could also cross the BBB and transduce the CNS cells after i.v. delivery, or if this property is specific to the double-stranded genome. In this aim, GFP-expressing ssAAV9 vectors were injected into the temporal vein of neonatal mice and GFP expression was analyzed 3 weeks after (in order to permit genome conversion into double-stranded DNA).
- Similar to that observed with scAAV9, ssAAV9-GFP proved to mediate CNS cell transduction after i.v. delivery, although its efficacy was lower than that of scAAV9. Again, the choroids plexus and ependyma cells expressed large amounts of GFP and many brain regions close to the cerebral ventricles were found to be transduced (
FIG. 6a ). For example, GFP-positive neurons were detected in the hippocampus and the habenular nuclei (FIG. 6a ) and in the median eminence (FIG. 6b ). Interestingly, some motor neuron-like cells were found to express GFP in the ventral spinal cord (FIG. 6c-e ). A few CNS cells were also found to express GFP after i.m. or i.p. delivery of the recombinant ssAAV9 (data not shown). - Altogether, these data suggest an unexpected ability of
serotype 9 AAV vectors—either conventional or self-complementary- to cross the BBB and transduce the CNS cells in neonatal mice, including the lower motor neurons, after a single intravenous injection in the neonatal mouse - Since the BBB is incompletely formed in neonatal mice, we evaluated whether the ability of the AAV9 vectors to transduce neural cells in newborn mice was preserved in adult mice. Ss and sc AAV9 vectors encoding for mSEAP (3·1011 vg or 1·1012 vg per mouse) were injected into the tail vein of adult mice and transgene expression in the CNS was analyzed four weeks thereafter. After i.v. delivery of scAAV9-mSEAP, a sustained expression of the transgene was found in many brain regions such as the median eminence (
FIG. 7f ), the hippocampus (FIG. 7g ) or the corpus callosum (FIG. 7h ). - Importantly, there were many mSEAP-positive cells and fibers throughout the spinal cord after i.v. delivery of
recombinant serotype 9 AAV vectors (FIG. 8a-g ). Again, a higher level of transgene expression was observed with the sc—than with the conventional ssAAV9 vector (FIG. 8a,b versus 8 c-g). - Similar injections using scAAV9-GFP demonstrated the superiority of scAAV9 for systemic gene delivery to the spinal cord. A high number of was found to express four weeks after i.v. injection of 2×1012 vg scAAV9, GFP was expressed in the spinal cord in both neuronal and glial cells, as demonstrated using immunostaining of the glial fibrillary acidic protein (GFAP), a marker of astrocytes (
FIG. 11 ). - Hence, our results show an efficient transduction of the CNS cells, including lower MNs and glial cells, after intravenous delivery of recombinant AAV9 vectors in adult mice in which the BBB is completely formed. This emphasizes the particular property of these vectors to pass from the circulation to the CNS parenchyma through the BBB, achieving widespread gene transfer to the nervous cells.
- A validation of this new CNS gene transfer strategy in large animal models is a prerequisite to a potential application in human clinics.
- We evaluated transgene expression in the spinal cord of LIX-1 kittens following intravenous delivery of recombinant scAAV9 vectors. Two days old kitten (one LIX-1 homozygous and one heterozygous) were injected into the jugular vein with GFP-expressing scAAV9. Ten days after, spinal cord tissue sections were analyzed for GFP expression using laser scanning confocal microscopy.
- A strong GFP signal was observed along the spinal cord from the cervical part to the cauda equina both in the gray and white matter, the expression pattern appearing similar in both the heterozygous and affected animals. Nerve fibers of the fasciculi gracilis and cuneatus dorsal sensory tracts expressed high levels of GFP (
FIG. 9a ). Moreover, GFP expression was detected in a number of cell bodies in the ventral spinal cord, after both observation of GFP fluorescence (FIG. 9a,c ) and immunohistochemical analysis (FIG. 9b-d ). A double-immunostaining analysis using antibodies against GFP and choline acetyl transferase (ChAT) showed that, in both SMA-affected and non-affected kitten, a significant part of the GFP-positive cells were motor neurons (FIG. 10 ). -
- Azzouz, M., A. Hottinger, et al. (2000). “Increased motoneuron survival and improved neuromuscular function in transgenic ALS mice after intraspinal injection of an adeno-associated virus encoding Bcl-2.” Hum Mol Genet 9(5): 803-11.
- Azzouz, M, et al., (2004). “Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy.” J Clin Invest. 114(12):1726-31
- Boillee, S., K. Yamanaka, et al. (2006). “Onset and progression in inherited ALS determined by motor neurons and microglia.” Science 312(5778): 1389-92
- Gearley, C. N. and J. H. Wolfe (2006). “Transduction characteristics of adeno-associated virus vectors expressing
cap serotypes 7, 8, 9, and Rh10 in the mouse brain.” Mol Ther 13(3): 528-37. - Daly, T. M., C. Vogler, et al. (1999). “Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease.” Proc Natl Acad Sci USA 96(5): 2296-300.
- Fu, H., J. Muenzer, et al. (2003). “Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain.” Mol Ther 8(6): 911-7.
- Fyfe, J. C., M. Menotti-Raymond, et al. (2006). “An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival.” Genome Res 16(9): 1084-90.
- Inagaki, K., S. Fuess, et al. (2006). “Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8.” Mol Ther 14(1): 45-53.
- Kaspar, B K, et al. (2003). “Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.” Science 301: 839-42.
- MacLean, H. E., G. L. Warne, et al. (1996). “Spinal and bulbar muscular atrophy: androgen receptor dysfunction caused by a trinucleotide repeat expansion.” J Neurol Sci 135(2): 149-57.
- McCarty, D. M., H. Fu, et al. (2003). “Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo.” Gene Ther 10(26): 2112-8.
- Monani, U. R. (2005). “Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease.” Neuron 48(6): 885-96.
- Pasinelli, P. and R. H. Brown (2006). “Molecular biology of amyotrophic lateral sclerosis: insights from genetics.” Nat Rev Neurosci 7(9): 710-23.
- Passini, M. A. and J. H. Wolfe (2001). “Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector.” J Virol 75(24): 12382-92.
- Scherrmann, J. M. (2002). Drug delivery to brain via the blood-brain barrier. Vascul Pharmacol. 38: 349-54.
- Xiao, X., J. Li, et al. (1998). “Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.” J Virol 72(3): 2224-32.
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/713,347 US20180066283A1 (en) | 2007-10-05 | 2017-09-22 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
US16/536,503 US11767538B2 (en) | 2007-10-05 | 2019-08-09 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07301435.9 | 2007-10-05 | ||
EP07301435A EP2058401A1 (en) | 2007-10-05 | 2007-10-05 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
PCT/EP2008/063297 WO2009043936A1 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
US73401610A | 2010-05-28 | 2010-05-28 | |
US15/713,347 US20180066283A1 (en) | 2007-10-05 | 2017-09-22 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/734,016 Division US9926574B2 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
PCT/EP2008/063297 Division WO2009043936A1 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/536,503 Division US11767538B2 (en) | 2007-10-05 | 2019-08-09 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20180066283A1 true US20180066283A1 (en) | 2018-03-08 |
Family
ID=39186802
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/734,016 Active 2029-03-10 US9926574B2 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
US15/713,347 Pending US20180066283A1 (en) | 2007-10-05 | 2017-09-22 | Widespread gene delivery to motor neurons using peripheral injection of aav vectors |
US16/536,503 Active US11767538B2 (en) | 2007-10-05 | 2019-08-09 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/734,016 Active 2029-03-10 US9926574B2 (en) | 2007-10-05 | 2008-10-03 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/536,503 Active US11767538B2 (en) | 2007-10-05 | 2019-08-09 | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
Country Status (18)
Country | Link |
---|---|
US (3) | US9926574B2 (en) |
EP (5) | EP2058401A1 (en) |
JP (2) | JP5620819B2 (en) |
CN (2) | CN105087650A (en) |
CA (2) | CA2701561C (en) |
CY (2) | CY1125608T1 (en) |
DK (2) | DK3505635T3 (en) |
ES (3) | ES2727034T3 (en) |
FI (1) | FI2212424T4 (en) |
FR (2) | FR20C1057I2 (en) |
HR (2) | HRP20220992T3 (en) |
HU (2) | HUE059864T2 (en) |
LT (2) | LT3505635T (en) |
NO (1) | NO2022048I1 (en) |
PL (2) | PL3505635T3 (en) |
PT (3) | PT2212424E (en) |
SI (2) | SI3505635T1 (en) |
WO (1) | WO2009043936A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021041489A1 (en) * | 2019-08-29 | 2021-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Adeno-associated viral vectors for crossing the human blood brain barrier |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120322861A1 (en) | 2007-02-23 | 2012-12-20 | Barry John Byrne | Compositions and Methods for Treating Diseases |
EP2019143A1 (en) * | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
DK3043181T3 (en) | 2008-01-15 | 2020-05-04 | Univ Leland Stanford Junior | MARKERS OF ACUTE MYELOID LEUKEMY STEM CELLS |
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US9415121B2 (en) | 2008-12-19 | 2016-08-16 | Nationwide Children's Hospital | Delivery of MECP2 polynucleotide using recombinant AAV9 |
US11219696B2 (en) | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
SG10201404528SA (en) | 2009-05-02 | 2014-10-30 | Genzyme Corp | Gene therapy for neurodegenerative disorders |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
US9546369B2 (en) | 2010-04-23 | 2017-01-17 | University Of Massachusetts | Multicistronic expression constructs |
EP2561075B1 (en) | 2010-04-23 | 2018-06-27 | University of Massachusetts | Aav-based treatment of cholesterol-related disorders |
EP2826860B1 (en) * | 2010-04-23 | 2018-08-22 | University of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
WO2012057363A1 (en) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | Adeno-associated virus virions for transferring genes into neural cells |
CA2870511C (en) | 2011-04-21 | 2023-08-08 | University Of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
US20130039888A1 (en) * | 2011-06-08 | 2013-02-14 | Nationwide Children's Hospital Inc. | Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders |
KR20150020250A (en) * | 2012-06-19 | 2015-02-25 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | Compositions and methods for treating diabetes |
AU2013279284A1 (en) | 2012-06-21 | 2015-01-29 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
EP3769789A1 (en) | 2012-08-01 | 2021-01-27 | Nationwide Children's Hospital | Intrathecal delivery of recombinant adeno-associated virus 9 |
JP2015529685A (en) | 2012-09-17 | 2015-10-08 | ザ・リサーチ・インスティテュート・アット・ネイションワイド・チルドレンズ・ホスピタルThe Research Institute Atnationwide Children’S Hospital | Compositions and methods for the treatment of amyotrophic lateral sclerosis |
MX2015015560A (en) * | 2013-05-15 | 2016-06-17 | Univ Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system. |
EP3702466B1 (en) | 2013-08-27 | 2022-12-28 | Research Institute at Nationwide Children's Hospital | Products and methods for treatment of amyotrophic lateral sclerosis |
EP3065784A4 (en) | 2013-11-05 | 2017-05-10 | The Research Institute at Nationwide Children's Hospital | COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS |
CA2939950C (en) * | 2014-03-09 | 2023-08-22 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of ornithine transcarbamylase (otc) deficiency |
EP2933335A1 (en) * | 2014-04-18 | 2015-10-21 | Genethon | A method of treating peripheral neuropathies and motor neuron diseases |
WO2015187825A2 (en) | 2014-06-03 | 2015-12-10 | University Of Massachusetts | Compositions and methods for modulating dysferlin expression |
BR112017001725A2 (en) | 2014-07-31 | 2018-02-14 | Association Inst De Myologie | amyotrophic lateral sclerosis treatment |
US10370432B2 (en) | 2014-10-03 | 2019-08-06 | University Of Massachusetts | Heterologous targeting peptide grafted AAVS |
EP3200830B1 (en) | 2014-10-03 | 2020-09-09 | University of Massachusetts | High efficiency library-identified aav vectors |
BR112017007737A2 (en) | 2014-10-21 | 2018-01-30 | Univ Massachusetts | recombinant aav variants and uses thereof |
EP3218484A4 (en) | 2014-11-14 | 2018-05-30 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
EP4344741A3 (en) | 2014-11-21 | 2024-08-28 | The University of North Carolina at Chapel Hill | Aav vectors targeted to the central nervous system |
EP3233131A1 (en) | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gene therapy for juvenile batten disease |
EP3256170B1 (en) | 2015-02-13 | 2020-09-23 | University of Massachusetts | Compositions and methods for transient delivery of nucleases |
US20180104289A1 (en) * | 2015-04-08 | 2018-04-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Viral gene therapy as treatment for cholesterol storage disease or disorder |
WO2016172008A1 (en) | 2015-04-24 | 2016-10-27 | University Of Massachusetts | Modified aav constructions and uses thereof |
CN108289965A (en) * | 2015-10-01 | 2018-07-17 | 戈勒尼股份有限公司 | The targeted expression and its application method of chloride channel |
AU2016341983B8 (en) * | 2015-10-21 | 2022-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Codon-optimized reduced-size ATP7A cDNA and uses for treatment of copper transport disorders |
WO2017070516A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Prostate-targeting adeno-associated virus serotype vectors |
WO2017070525A1 (en) | 2015-10-22 | 2017-04-27 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
US11826433B2 (en) | 2016-02-02 | 2023-11-28 | University Of Massachusetts | Method to enhance the efficiency of systemic AAV gene delivery to the central nervous system |
EP3413928B1 (en) | 2016-02-12 | 2022-04-20 | University of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
WO2017176929A1 (en) | 2016-04-05 | 2017-10-12 | University Of Massachusetts | Compositions and methods for selective inhibition of grainyhead-like protein expression |
IL305449A (en) | 2016-04-15 | 2023-10-01 | Univ Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
CA3024536A1 (en) | 2016-06-13 | 2017-12-21 | The University Of North Carolina At Chapel Hill | Optimized cln1 genes and expression cassettes and their use |
US11882815B2 (en) | 2016-06-15 | 2024-01-30 | University Of Massachusetts | Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells |
JP2019531787A (en) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Biomedical targeting and delivery method and apparatus and system for performing the same |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
US11578340B2 (en) | 2016-10-13 | 2023-02-14 | University Of Massachusetts | AAV capsid designs |
CN108524952A (en) * | 2017-03-06 | 2018-09-14 | 复旦大学 | Adeno-associated virus AAV9 and its purposes in the preparation for preparing treatment dagger-axe Xie Shi diseases |
WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
EP3654860A1 (en) | 2017-07-17 | 2020-05-27 | Voyager Therapeutics, Inc. | Trajectory array guide system |
TWI722310B (en) | 2017-08-03 | 2021-03-21 | 美商航海家醫療公司 | Compositions and methods for delivery of aav |
EP3684938A1 (en) | 2017-09-22 | 2020-07-29 | The Trustees of the University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
TW202413649A (en) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | Treatment of amyotrophic lateral sclerosis (als) |
JP2021502123A (en) * | 2017-11-08 | 2021-01-28 | アヴェクシス インコーポレーテッド | Means and methods for preparing viral vectors and their use |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
JP7244547B2 (en) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Adeno-associated virus compositions and methods of use thereof for restoring F8 gene function |
US12091435B2 (en) | 2018-04-03 | 2024-09-17 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
JP7406677B2 (en) | 2018-04-03 | 2023-12-28 | ギンコ バイオワークス インコーポレイテッド | Viral vectors that evade antibodies |
WO2019200016A1 (en) | 2018-04-10 | 2019-10-17 | President And Fellows Of Harvard College | Aav vectors encoding clarin-1 or gjb2 and uses thereof |
JP2021523914A (en) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Compositions and Methods for Treating Parkinson's Disease |
US20210230632A1 (en) | 2018-05-15 | 2021-07-29 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
WO2020010035A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Cannula system |
CN112567035A (en) | 2018-07-02 | 2021-03-26 | 沃雅戈治疗公司 | Treatment of amyotrophic lateral sclerosis and spinal cord related disorders |
MX2021000810A (en) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Systems and methods for producing gene therapy formulations. |
TW202035689A (en) | 2018-10-04 | 2020-10-01 | 美商航海家醫療公司 | Methods for measuring the titer and potency of viral vector particles |
US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
TW202039858A (en) | 2019-01-18 | 2020-11-01 | 美商航海家醫療公司 | Methods and systems for producing aav particles |
US20220378941A1 (en) * | 2019-02-05 | 2022-12-01 | The Trustees Of Princeton University | Recombinant nucleic acids containing alphaherpesvirus promoter sequences |
CN109706176A (en) * | 2019-03-12 | 2019-05-03 | 青岛大学附属医院 | Transfection dorsal root ganglion satellite spongiocyte adenovirus vector construct method can be targeted |
WO2020191300A1 (en) | 2019-03-21 | 2020-09-24 | Stridebio, Inc. | Recombinant adeno-associated virus vectors |
KR20210143869A (en) * | 2019-03-28 | 2021-11-29 | 더 제너럴 하스피탈 코포레이션 | Engineered adeno-associated (AAV) vectors for transgene expression |
WO2021007529A1 (en) * | 2019-07-10 | 2021-01-14 | Locanabio, Inc. | Rna-targeting knockdown and replacement compositions and methods for use |
WO2021046155A1 (en) | 2019-09-03 | 2021-03-11 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
TW202128736A (en) | 2019-10-17 | 2021-08-01 | 美商史崔德生物公司 | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
TW202140791A (en) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | Methods of treating phenylketonuria |
EP4135841A1 (en) | 2020-04-15 | 2023-02-22 | Voyager Therapeutics, Inc. | Tau binding compounds |
KR20230022175A (en) | 2020-05-13 | 2023-02-14 | 보이저 테라퓨틱스, 인크. | Orientation of AAV capsids |
TW202208632A (en) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | Adeno-associated virus compositions for restoring pah gene function and methods of use thereof |
AR123288A1 (en) | 2020-08-19 | 2022-11-16 | Stridebio Inc | ADENO ASSOCIATED VIRUS VECTORS FOR THE TREATMENT OF RETT SYNDROME |
CN112121179A (en) * | 2020-09-15 | 2020-12-25 | 山东兴瑞生物科技有限公司 | Composition and application thereof in treating spinal muscular atrophy |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
CN115708866A (en) * | 2021-08-23 | 2023-02-24 | 中国科学院深圳先进技术研究院 | Application of bone origin factor RANKL in preparation of medicine or medicine composition for regulating and controlling central nervous system homeostasis |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
AU2022379918A1 (en) | 2021-11-02 | 2024-04-18 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
AU2023217698A1 (en) | 2022-02-08 | 2024-07-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
TW202417466A (en) | 2022-06-02 | 2024-05-01 | 美商航海家醫療公司 | Aav capsid variants and uses thereof |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
CN116064671A (en) * | 2022-08-10 | 2023-05-05 | 深圳先进技术研究院 | Application of gene delivery system in delivering genes to microglia |
TW202428602A (en) | 2022-09-15 | 2024-07-16 | 美商航海家醫療公司 | Tau binding compounds |
WO2024145474A2 (en) | 2022-12-29 | 2024-07-04 | Voyager Therapeutics, Inc. | Compositions and methods for regulating mapt |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0832266A4 (en) | 1995-06-07 | 2000-06-28 | Univ Yale | Oral delivery of adeno-associated viral vectors |
US20040076613A1 (en) | 2000-11-03 | 2004-04-22 | Nicholas Mazarakis | Vector system |
FR2756297B1 (en) | 1996-11-22 | 1999-01-08 | Centre Nat Rech Scient | PROCESS FOR PRODUCING RECOMBINANT VIRUSES |
AU8672198A (en) | 1997-07-31 | 1999-02-22 | Chiron Corporation | Method enabling readministration of aav vector via immunosuppression of host |
CA2348382C (en) | 1998-11-10 | 2013-09-17 | The University Of North Carolina At Chapel Hill | Chimeric parvovirus vectors and methods of making and administering the same |
US6498244B1 (en) | 1999-05-28 | 2002-12-24 | Cell Genesys, Inc. | Adeno-associated virus capsid immunologic determinants |
AU1071701A (en) | 1999-09-29 | 2001-04-30 | Trustees Of The University Of Pennsylvania, The | Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor |
US6582692B1 (en) | 1999-11-17 | 2003-06-24 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
ATE318923T1 (en) | 2000-06-01 | 2006-03-15 | Univ North Carolina | DOUBLE STRANDED PARVOVIRUS VECTORS |
AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
WO2003004660A1 (en) | 2001-07-03 | 2003-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of administering vectors to synaptically connected neurons |
CA2406745C (en) * | 2001-11-13 | 2006-01-10 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
DK1463805T3 (en) | 2001-12-17 | 2015-01-19 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 9, vectors containing these as well as their uses |
AU2002359786A1 (en) | 2001-12-19 | 2003-07-09 | Hiroaki Mizukami | Adeno-associated virus-mediated delivery of gdnf to skeletal muscles |
EP1478236B1 (en) | 2001-12-21 | 2009-02-11 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery to motor neurons |
US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
US20060018882A1 (en) * | 2004-06-21 | 2006-01-26 | Kaemmerer William F | Medical devices and methods for delivering compositions to cells |
EP1608410A2 (en) * | 2003-03-31 | 2005-12-28 | University of Iowa Research Foundation | Pharmico-gene theraphy of epithelial sodium channel associated disoders |
EP1633871A4 (en) * | 2003-06-03 | 2010-02-17 | Benitec Australia Ltd | Double-stranded nucleic acid |
ES2627913T3 (en) | 2003-06-19 | 2017-08-01 | Genzyme Corporation | AAV virions with reduced immunoreactivity and uses thereof |
US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
CA3072423A1 (en) | 2003-09-30 | 2005-04-14 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
US7723288B2 (en) * | 2003-10-14 | 2010-05-25 | Neurologix, Inc. | Methods and compositions for the treatment of neurological disease |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
WO2005056807A2 (en) | 2003-12-04 | 2005-06-23 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Bovine adeno-associated viral (baav) vector and uses thereof |
WO2005072364A2 (en) | 2004-01-27 | 2005-08-11 | University Of Florida | A modified baculovirus expression system for production of pseudotyped raav vector |
WO2005097206A2 (en) * | 2004-04-06 | 2005-10-20 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein a-i and apolipoprotein a-i milano |
US20060110364A1 (en) * | 2004-08-20 | 2006-05-25 | Ludwig Institute For Cancer Research | Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors |
WO2006119432A2 (en) | 2005-04-29 | 2006-11-09 | The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services | Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes |
AU2006242129A1 (en) | 2005-05-02 | 2006-11-09 | Genzyme Corporation | Gene therapy for spinal cord disorders |
US7867484B2 (en) * | 2006-01-27 | 2011-01-11 | University Of North Carolina At Chapel Hill | Heparin and heparan sulfate binding chimeric vectors |
US20070280906A1 (en) | 2006-06-03 | 2007-12-06 | Ognjen Petras | Method to generate mirrored adenoassociated viral vectors |
US20100221225A1 (en) * | 2007-02-23 | 2010-09-02 | University Of Florida Research Foundation, Inc | Compositions and methods for treating glycogen storage diseases |
US10696983B2 (en) | 2007-05-30 | 2020-06-30 | The Trustees Of The University Of Pennsylvania | Method for transducing cells with primary cilia |
EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
US20090087413A1 (en) | 2007-10-01 | 2009-04-02 | Alcon Research, Ltd. | Self-complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
EP2058401A1 (en) * | 2007-10-05 | 2009-05-13 | Genethon | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors |
US11219696B2 (en) * | 2008-12-19 | 2022-01-11 | Nationwide Children's Hospital | Delivery of polynucleotides using recombinant AAV9 |
-
2007
- 2007-10-05 EP EP07301435A patent/EP2058401A1/en not_active Withdrawn
-
2008
- 2008-10-03 SI SI200832199T patent/SI3505635T1/en unknown
- 2008-10-03 DK DK19158152.9T patent/DK3505635T3/en active
- 2008-10-03 PT PT88367768T patent/PT2212424E/en unknown
- 2008-10-03 ES ES12180951T patent/ES2727034T3/en active Active
- 2008-10-03 CN CN201510438197.1A patent/CN105087650A/en active Pending
- 2008-10-03 EP EP21161090.2A patent/EP3854878A1/en active Pending
- 2008-10-03 PT PT12180951T patent/PT2527457T/en unknown
- 2008-10-03 CA CA2701561A patent/CA2701561C/en active Active
- 2008-10-03 EP EP12180951.1A patent/EP2527457B1/en not_active Revoked
- 2008-10-03 US US12/734,016 patent/US9926574B2/en active Active
- 2008-10-03 DK DK08836776.8T patent/DK2212424T3/en active
- 2008-10-03 WO PCT/EP2008/063297 patent/WO2009043936A1/en active Application Filing
- 2008-10-03 PL PL19158152.9T patent/PL3505635T3/en unknown
- 2008-10-03 HU HUE19158152A patent/HUE059864T2/en unknown
- 2008-10-03 ES ES19158152T patent/ES2924892T3/en active Active
- 2008-10-03 CA CA2999607A patent/CA2999607A1/en not_active Abandoned
- 2008-10-03 EP EP08836776.8A patent/EP2212424B2/en active Active
- 2008-10-03 PT PT191581529T patent/PT3505635T/en unknown
- 2008-10-03 LT LTEP19158152.9T patent/LT3505635T/en unknown
- 2008-10-03 SI SI200831238T patent/SI2212424T1/en unknown
- 2008-10-03 ES ES08836776T patent/ES2482094T5/en active Active
- 2008-10-03 PL PL08836776T patent/PL2212424T3/en unknown
- 2008-10-03 CN CN2008801174130A patent/CN101883859A/en active Pending
- 2008-10-03 HR HRP20220992TT patent/HRP20220992T3/en unknown
- 2008-10-03 EP EP19158152.9A patent/EP3505635B1/en active Active
- 2008-10-03 JP JP2010527467A patent/JP5620819B2/en active Active
-
2014
- 2014-07-01 JP JP2014136031A patent/JP6309373B2/en active Active
- 2014-07-07 HR HRP20140643AT patent/HRP20140643T1/en unknown
-
2017
- 2017-09-22 US US15/713,347 patent/US20180066283A1/en active Pending
-
2019
- 2019-08-09 US US16/536,503 patent/US11767538B2/en active Active
-
2020
- 2020-11-17 FR FR20C1057C patent/FR20C1057I2/en active Active
- 2020-11-17 FI FIEP08836776.8T patent/FI2212424T4/en active
-
2022
- 2022-08-16 CY CY20221100551T patent/CY1125608T1/en unknown
- 2022-11-16 LT LTPA2022525C patent/LTPA2022525I1/lt unknown
- 2022-11-16 CY CY2022034C patent/CY2022034I1/en unknown
- 2022-11-16 NO NO2022048C patent/NO2022048I1/en unknown
- 2022-11-16 HU HUS2200047C patent/HUS2200047I1/en unknown
- 2022-11-17 FR FR22C1056C patent/FR22C1056I1/en active Active
Non-Patent Citations (2)
Title |
---|
Crystal HUMAN GENE THERAPY 15:1131–1154 (Year: 2004) * |
Janson et al HUMAN GENE THERAPY 13:1391–1412 (Year: 2002) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021041489A1 (en) * | 2019-08-29 | 2021-03-04 | The Board Of Trustees Of The Leland Stanford Junior University | Adeno-associated viral vectors for crossing the human blood brain barrier |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11767538B2 (en) | Widespread gene delivery to motor neurons using peripheral injection of AAV vectors | |
US20230374547A1 (en) | Cns gene delivery using peripheral administration of aav vectors | |
US20160361440A1 (en) | Widespread gene delivery of gene therapy vectors | |
EP3364970B1 (en) | Gene therapy for use in treating lysosomal storage disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |